{"url_path":"/sec/cers/10-k/2026/item-16","section_key":"item-16","section_title":"Item 16 Form 10-K Summary","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-03-02","source_url":"https://www.sec.gov/Archives/edgar/data/1020214/0001193125-26-085678-index.html","accession_number":"0001193125-26-085678","cik":"0001020214","ticker":"CERS","issuer_name":"CERUS CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/1020214/0001193125-26-085678-index.html","primary_entity_key":"0001020214","primary_entity_name":"CERUS CORP"},"word_count":16392,"has_tables":true,"body_markdown":"Item 16. Form 10-K Summary\n\n \n\nNone.\n\n \n\n87\n\n \n\nReport of Independent Registered Public Accounting Firm\n\n \n\nTo the Shareholders and the Board of Directors of Cerus Corporation\n\nOpinion on the Financial Statements\n\nWe have audited the accompanying consolidated balance sheets of Cerus Corporation (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.\n\nWe also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March 2, 2026 expressed an unqualified opinion thereon.\n\n \n\nBasis for Opinion\n\nThese financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.\n\nWe conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.\n\n \n\nCritical Audit Matter\n\nThe critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosures to which it relates.\n\n \n\n \n\n \n\nRevenue Recognition\n\nDescription of the Matter\n\n \n\nIn the year ended December 31, 2025, the Company recognized $206.1 million of product revenue. As discussed in Note 2 to the consolidated financial statements, product revenue from the sale of illuminators, disposable kits (platelet and plasma systems), INTERCEPT Fibrinogen Complex, spare parts and storage solutions are recognized upon the transfer of control of the products to the customer for an amount that reflects the consideration which the Company expects to receive in exchange for those products.\n\nAuditing the Company’s revenue recognition was challenging due to the volume of transactions across multiple geographies and customer types, including hospitals, blood centers, and government agencies. This included assessing whether revenue was recognized at the appropriate point in time based on transfer of control and verifying the accuracy of recorded transactions.\n\nHow We Addressed the Matter in Our Audit\n\n \n\nWe obtained an understanding of, evaluated the design and tested the operating effectiveness of controls over the Company’s revenue recognition process, including testing the automated controls which are applicable to\n\n88\n\n \n\n \n\n \n\nprocessing of all transactions.\n  \n\nTo test product revenue, our audit procedures included, among others, performing sample testing of selected sales transactions, and tracing such transactions to supporting third party documentation, and performing analytical procedures to trace revenue journal entries to accounts receivable and cash collections. We also tested a sample of cash collections to source documents.\n\n \n\n/s/ Ernst & Young LLP\n\nWe have served as the Company’s auditor since 1991.\n\n \n\nSan Francisco, California\n\n \n\nMarch 2, 2026\n\n \n\n89\n\n \n\nCERUS CORPORATION\n\nCONSOLIDATED BALANCE SHEETS\n\n(in thousands, except per share amounts)\n\n \n\n \n\nDecember 31,\n\n \n\n \n\nDecember 31,\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\nASSETS\n\n \n\n \n\n \n\n \n\n \n\n \n\nCurrent assets:\n\n \n\n \n\n \n\n \n\n \n\n \n\nCash and cash equivalents\n\n \n\n$\n\n19,961\n\n \n\n \n\n$\n\n20,266\n\n \n\nShort-term investments\n\n \n\n \n\n62,918\n\n \n\n \n\n \n\n60,186\n\n \n\nAccounts receivable, net\n\n \n\n \n\n30,374\n\n \n\n \n\n \n\n29,777\n\n \n\nCurrent inventories\n\n \n\n \n\n56,101\n\n \n\n \n\n \n\n38,150\n\n \n\nPrepaid and other current assets\n\n \n\n \n\n5,030\n\n \n\n \n\n \n\n3,643\n\n \n\nTotal current assets\n\n \n\n \n\n174,384\n\n \n\n \n\n \n\n152,022\n\n \n\nNon-current assets:\n\n \n\n \n\n \n\n \n\n \n\n \n\nProperty and equipment, net\n\n \n\n \n\n9,204\n\n \n\n \n\n \n\n7,154\n\n \n\nOperating lease right-of-use assets\n\n \n\n \n\n10,124\n\n \n\n \n\n \n\n8,384\n\n \n\nGoodwill\n\n \n\n \n\n1,316\n\n \n\n \n\n \n\n1,316\n\n \n\nRestricted cash\n\n \n\n \n\n639\n\n \n\n \n\n \n\n1,095\n\n \n\nNon-current inventories\n\n \n\n \n\n15,143\n\n \n\n \n\n \n\n14,145\n\n \n\nOther assets\n\n \n\n \n\n11,049\n\n \n\n \n\n \n\n16,801\n\n \n\nTotal assets\n\n \n\n$\n\n221,859\n\n \n\n \n\n$\n\n200,917\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nLIABILITIES AND STOCKHOLDERS’ EQUITY\n\n \n\n \n\n \n\n \n\n \n\n \n\nCurrent liabilities:\n\n \n\n \n\n \n\n \n\n \n\n \n\nAccounts payable\n\n \n\n$\n\n28,008\n\n \n\n \n\n$\n\n21,695\n\n \n\nAccrued liabilities\n\n \n\n \n\n25,271\n\n \n\n \n\n \n\n18,943\n\n \n\nDebt – current\n\n \n\n \n\n43,343\n\n \n\n \n\n \n\n19,297\n\n \n\nOperating lease liabilities – current\n\n \n\n \n\n2,905\n\n \n\n \n\n \n\n2,275\n\n \n\nDeferred revenue\n\n \n\n \n\n1,274\n\n \n\n \n\n \n\n1,398\n\n \n\nTotal current liabilities\n\n \n\n \n\n100,801\n\n \n\n \n\n \n\n63,608\n\n \n\nNon-current liabilities:\n\n \n\n \n\n \n\n \n\n \n\n \n\nDebt – non-current\n\n \n\n \n\n40,545\n\n \n\n \n\n \n\n64,862\n\n \n\nOperating lease liabilities – non-current\n\n \n\n \n\n10,153\n\n \n\n \n\n \n\n11,663\n\n \n\nOther non-current liabilities\n\n \n\n \n\n5,395\n\n \n\n \n\n \n\n3,888\n\n \n\nTotal liabilities\n\n \n\n \n\n156,894\n\n \n\n \n\n \n\n144,021\n\n \n\nCommitments and contingencies (Note 10)\n\n \n\n \n\n \n\n \n\n \n\n \n\nStockholders’ equity:\n\n \n\n \n\n \n\n \n\n \n\n \n\nPreferred stock, $0.001 par value; 5,000 shares authorized, issuable in series; zero shares issued and outstanding at December 31, 2025 and 2024, respectively\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nCommon stock, $0.001 par value; 400,000 and 400,000 shares authorized; 192,142 and 185,766 shares issued and outstanding at December 31, 2025 and 2024, respectively\n\n \n\n \n\n192\n\n \n\n \n\n \n\n186\n\n \n\nAdditional paid-in capital\n\n \n\n \n\n1,145,343\n\n \n\n \n\n \n\n1,121,887\n\n \n\nAccumulated other comprehensive loss\n\n \n\n \n\n(156\n\n)\n\n \n\n \n\n(400\n\n)\n\nAccumulated deficit\n\n \n\n \n\n(1,081,155\n\n)\n\n \n\n \n\n(1,065,528\n\n)\n\nTotal Cerus Corporation stockholders’ equity\n\n \n\n \n\n64,224\n\n \n\n \n\n \n\n56,145\n\n \n\nNoncontrolling interest\n\n \n\n \n\n741\n\n \n\n \n\n \n\n751\n\n \n\nTotal liabilities and stockholders’ equity\n\n \n\n$\n\n221,859\n\n \n\n \n\n$\n\n200,917\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nSee accompanying Notes to Consolidated Financial Statements.\n\n \n\n90\n\n \n\nCERUS CORPORATION\n\nCONSOLIDATED STATEMENTS OF OPERATIONS\n\n(in thousands, except per share amounts)\n\n \n\n \n\n \n\n \n\nYear Ended December 31,\n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nProduct revenue\n\n$\n\n206,133\n\n \n\n \n\n$\n\n180,270\n\n \n\n \n\n$\n\n156,367\n\n \n\nCost of product revenue\n\n \n\n93,845\n\n \n\n \n\n \n\n80,748\n\n \n\n \n\n \n\n69,967\n\n \n\nGross profit on product revenue\n\n \n\n112,288\n\n \n\n \n\n \n\n99,522\n\n \n\n \n\n \n\n86,400\n\n \n\nGovernment contract revenue\n\n \n\n27,665\n\n \n\n \n\n \n\n21,051\n\n \n\n \n\n \n\n30,430\n\n \n\nOperating expenses:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nResearch and development\n\n \n\n67,720\n\n \n\n \n\n \n\n58,907\n\n \n\n \n\n \n\n67,639\n\n \n\nSelling, general and administrative\n\n \n\n80,914\n\n \n\n \n\n \n\n75,891\n\n \n\n \n\n \n\n75,516\n\n \n\nRestructuring\n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n3,728\n\n \n\nTotal operating expenses\n\n \n\n148,634\n\n \n\n \n\n \n\n134,798\n\n \n\n \n\n \n\n146,883\n\n \n\nLoss from operations\n\n \n\n(8,681\n\n)\n\n \n\n \n\n(14,225\n\n)\n\n \n\n \n\n(30,053\n\n)\n\nNon-operating expense, net:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nForeign exchange (loss) gain\n\n \n\n(1,275\n\n)\n\n \n\n \n\n370\n\n \n\n \n\n \n\n(648\n\n)\n\nInterest expense\n\n \n\n(8,343\n\n)\n\n \n\n \n\n(8,877\n\n)\n\n \n\n \n\n(8,386\n\n)\n\nOther income, net\n\n \n\n3,016\n\n \n\n \n\n \n\n1,976\n\n \n\n \n\n \n\n1,765\n\n \n\nTotal non-operating expense, net\n\n \n\n(6,602\n\n)\n\n \n\n \n\n(6,531\n\n)\n\n \n\n \n\n(7,269\n\n)\n\nLoss before income taxes\n\n \n\n(15,283\n\n)\n\n \n\n \n\n(20,756\n\n)\n\n \n\n \n\n(37,322\n\n)\n\nProvision for income taxes\n\n \n\n354\n\n \n\n \n\n \n\n205\n\n \n\n \n\n \n\n325\n\n \n\nNet loss\n\n \n\n(15,637\n\n)\n\n \n\n \n\n(20,961\n\n)\n\n \n\n \n\n(37,647\n\n)\n\nNet loss attributable to noncontrolling interest\n\n \n\n(10\n\n)\n\n \n\n \n\n(43\n\n)\n\n \n\n \n\n(158\n\n)\n\nNet loss attributable to Cerus Corporation\n\n$\n\n(15,627\n\n)\n\n \n\n$\n\n(20,918\n\n)\n\n \n\n$\n\n(37,489\n\n)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nNet loss per share attributable to Cerus Corporation\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBasic and diluted\n\n$\n\n(0.08\n\n)\n\n \n\n$\n\n(0.11\n\n)\n\n \n\n$\n\n(0.21\n\n)\n\nWeighted average shares outstanding:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBasic and diluted\n\n \n\n190,594\n\n \n\n \n\n \n\n184,563\n\n \n\n \n\n \n\n180,270\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nSee accompanying Notes to Consolidated Financial Statements.\n\n \n\n91\n\n \n\nCERUS CORPORATION\n\nCONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS\n\n(in thousands)\n\n \n\n \n\n \n\n \n\n \n\n \n\nYear Ended December 31,\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nNet loss\n\n \n\n$\n\n(15,637\n\n)\n\n \n\n$\n\n(20,961\n\n)\n\n \n\n$\n\n(37,647\n\n)\n\nOther comprehensive income (loss)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nForeign currency translation adjustment\n\n \n\n \n\n19\n\n \n\n \n\n \n\n(14\n\n)\n\n \n\n \n\n(85\n\n)\n\nUnrealized gains on available-for-sale investments, net of taxes\n\n \n\n \n\n225\n\n \n\n \n\n \n\n888\n\n \n\n \n\n \n\n1,598\n\n \n\nComprehensive loss\n\n \n\n \n\n(15,393\n\n)\n\n \n\n \n\n(20,087\n\n)\n\n \n\n \n\n(36,134\n\n)\n\nComprehensive loss attributable to noncontrolling interest\n\n \n\n \n\n(10\n\n)\n\n \n\n \n\n(43\n\n)\n\n \n\n \n\n(158\n\n)\n\nTotal comprehensive loss attributable to Cerus Corporation\n\n \n\n$\n\n(15,383\n\n)\n\n$\n\n(20,044\n\n)\n\n$\n\n(35,976\n\n)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nSee accompanying Notes to Consolidated Financial Statements.\n\n \n\n92\n\n \n\nCERUS CORPORATION\n\nCONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY\n\n(in thousands)\n\n \n\n \n\n \n\n \n\nCommon Stock\n\n \n\n \n\nAdditional\nPaid-in\n\n \n\n \n\nAccumulated\nOther\nComprehensive\n\n \n\n \n\nAccumulated\n\n \n\n \n\nNoncontrolling\n\n \n\n \n\nTotal\nStockholders’\n\n \n\n \n\n \n\nShares\n\n \n\n \n\nAmount\n\n \n\n \n\nCapital\n\n \n\n \n\nIncome (Loss)\n\n \n\n \n\nDeficit\n\n \n\n \n\nInterest\n\n \n\n \n\nEquity\n\n \n\nBalance at December 31, 2022\n\n \n\n \n\n177,582\n\n \n\n \n\n$\n\n177\n\n \n\n \n\n$\n\n1,077,341\n\n \n\n \n\n$\n\n(2,787\n\n)\n\n \n\n$\n\n(1,007,121\n\n)\n\n \n\n$\n\n952\n\n \n\n \n\n \n\n68,562\n\n \n\nIssuance of common stock from exercise of stock options, vesting of\n  restricted stock units, and ESPP purchases\n\n \n\n \n\n3,666\n\n \n\n \n\n \n\n4\n\n \n\n \n\n \n\n741\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n745\n\n \n\nStock-based compensation\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n20,271\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n20,271\n\n \n\nOther comprehensive income\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n1,513\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n1,513\n\n \n\nNet loss\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n(37,489\n\n)\n\n \n\n \n\n(158\n\n)\n\n \n\n \n\n(37,647\n\n)\n\nBalance at December 31, 2023\n\n \n\n \n\n181,248\n\n \n\n \n\n$\n\n181\n\n \n\n \n\n$\n\n1,098,353\n\n \n\n \n\n$\n\n(1,274\n\n)\n\n \n\n$\n\n(1,044,610\n\n)\n\n \n\n$\n\n794\n\n \n\n \n\n$\n\n53,444\n\n \n\nIssuance of common stock from vesting of restricted stock units and\n  ESPP purchases\n\n \n\n \n\n4,518\n\n \n\n \n\n \n\n5\n\n \n\n \n\n \n\n667\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n672\n\n \n\nStock-based compensation\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n22,867\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n22,867\n\n \n\nOther comprehensive income\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n874\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n874\n\n \n\nNet loss\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n(20,918\n\n)\n\n \n\n \n\n(43\n\n)\n\n \n\n \n\n(20,961\n\n)\n\nBalance at December 31, 2024\n\n \n\n \n\n185,766\n\n \n\n \n\n$\n\n186\n\n \n\n \n\n$\n\n1,121,887\n\n \n\n \n\n$\n\n(400\n\n)\n\n \n\n$\n\n(1,065,528\n\n)\n\n \n\n$\n\n751\n\n \n\n \n\n$\n\n56,896\n\n \n\nIssuance of common stock from vesting of restricted stock units and\n  ESPP purchases\n\n \n\n \n\n6,376\n\n \n\n \n\n \n\n6\n\n \n\n \n\n \n\n589\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n595\n\n \n\nStock-based compensation\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n22,867\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n22,867\n\n \n\nOther comprehensive income\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n244\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n244\n\n \n\nNet loss\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n(15,627\n\n)\n\n \n\n \n\n(10\n\n)\n\n \n\n \n\n(15,637\n\n)\n\nBalance at December 31, 2025\n\n \n\n \n\n192,142\n\n \n\n \n\n$\n\n192\n\n \n\n \n\n$\n\n1,145,343\n\n \n\n \n\n$\n\n(156\n\n)\n\n \n\n$\n\n(1,081,155\n\n)\n\n \n\n$\n\n741\n\n \n\n \n\n$\n\n64,965\n\n \n\n \n\nSee accompanying Notes to Consolidated Financial Statements.\n\n \n\n93\n\n \n\nCERUS CORPORATION\n\nCONSOLIDATED STATEMENTS OF CASH FLOWS\n\n(in thousands)\n\n \n\n \n\n \n\nYear Ended\n\n \n\n \n\n \n\nDecember 31,\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nOperating activities\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nNet loss\n\n \n\n$\n\n(15,637\n\n)\n\n \n\n$\n\n(20,961\n\n)\n\n \n\n$\n\n(37,647\n\n)\n\nAdjustments to reconcile net loss to net cash provided by (used in) operating activities:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDepreciation and amortization\n\n \n\n \n\n1,426\n\n \n\n \n\n \n\n1,855\n\n \n\n \n\n \n\n2,599\n\n \n\nStock-based compensation\n\n \n\n \n\n22,867\n\n \n\n \n\n \n\n22,867\n\n \n\n \n\n \n\n20,271\n\n \n\nNon-cash operating lease cost\n\n \n\n \n\n2,532\n\n \n\n \n\n \n\n2,482\n\n \n\n \n\n \n\n2,308\n\n \n\nNet (gain) loss on sale of available-for-sale securities\n\n \n\n \n\n(6\n\n)\n\n \n\n \n\n7\n\n \n\n \n\n \n\n54\n\n \n\nUnrealized gain on investments\n\n \n\n \n\n(204\n\n)\n\n \n\n \n\n(135\n\n)\n\n \n\n \n\n(170\n\n)\n\nLoss on disposal of fixed assets\n\n \n\n \n\n—\n\n \n\n \n\n \n\n3\n\n \n\n \n\n \n\n65\n\n \n\nImpairment charges for facilities consolidation\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n1,698\n\n \n\nNon-cash interest expense\n\n \n\n \n\n398\n\n \n\n \n\n \n\n398\n\n \n\n \n\n \n\n374\n\n \n\nForeign currency remeasurement loss (gain)\n\n \n\n \n\n290\n\n \n\n \n\n \n\n(388\n\n)\n\n \n\n \n\n(685\n\n)\n\nChanges in operating assets and liabilities:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAccounts receivable\n\n \n\n \n\n(396\n\n)\n\n \n\n \n\n5,504\n\n \n\n \n\n \n\n(1,102\n\n)\n\nInventories\n\n \n\n \n\n(14,682\n\n)\n\n \n\n \n\n7,030\n\n \n\n \n\n \n\n(14,947\n\n)\n\nPrepaid and other assets\n\n \n\n \n\n(1,627\n\n)\n\n \n\n \n\n(3,025\n\n)\n\n \n\n \n\n(994\n\n)\n\nAccounts payable\n\n \n\n \n\n5,725\n\n \n\n \n\n \n\n(1,477\n\n)\n\n \n\n \n\n(7,335\n\n)\n\nAccrued liabilities and other non-current liabilities\n\n \n\n \n\n4,275\n\n \n\n \n\n \n\n(2,198\n\n)\n\n \n\n \n\n(9,070\n\n)\n\nDeferred revenue\n\n \n\n \n\n(124\n\n)\n\n \n\n \n\n(603\n\n)\n\n \n\n \n\n1,413\n\n \n\nNet cash provided by (used in) operating activities\n\n \n\n \n\n4,837\n\n \n\n \n\n \n\n11,359\n\n \n\n \n\n \n\n(43,168\n\n)\n\nInvesting activities\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCapital expenditures\n\n \n\n \n\n(3,729\n\n)\n\n \n\n \n\n(2,837\n\n)\n\n \n\n \n\n(4,597\n\n)\n\nPurchases of investments\n\n \n\n \n\n(42,777\n\n)\n\n \n\n \n\n(42,975\n\n)\n\n \n\n \n\n(2,486\n\n)\n\nProceeds from maturities and sale of investments\n\n \n\n \n\n40,341\n\n \n\n \n\n \n\n37,682\n\n \n\n \n\n \n\n15,707\n\n \n\nNet cash (used in) provided by investing activities\n\n \n\n \n\n(6,165\n\n)\n\n \n\n \n\n(8,130\n\n)\n\n \n\n \n\n8,624\n\n \n\nFinancing activities\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nNet proceeds from equity incentives\n\n \n\n \n\n595\n\n \n\n \n\n \n\n804\n\n \n\n \n\n \n\n925\n\n \n\nNet costs from public offerings\n\n \n\n \n\n(35\n\n)\n\n \n\n \n\n(137\n\n)\n\n \n\n \n\n(175\n\n)\n\nNet (payments on) proceeds from revolving line of credit\n\n \n\n \n\n(329\n\n)\n\n \n\n \n\n(703\n\n)\n\n \n\n \n\n5,091\n\n \n\nProceeds from loans, net of issuance costs\n\n \n\n \n\n—\n\n \n\n \n\n \n\n5,000\n\n \n\n \n\n \n\n4,832\n\n \n\nNet cash provided by financing activities\n\n \n\n \n\n231\n\n \n\n \n\n \n\n4,964\n\n \n\n \n\n \n\n10,673\n\n \n\nEffect of exchange rates on cash, cash equivalents, and restricted cash\n\n \n\n \n\n336\n\n \n\n \n\n \n\n(191\n\n)\n\n \n\n \n\n(128\n\n)\n\nNet (decrease) increase in cash, cash equivalents, and restricted cash\n\n \n\n \n\n(761\n\n)\n\n \n\n \n\n8,002\n\n \n\n \n\n \n\n(23,999\n\n)\n\nCash, cash equivalents, and restricted cash, beginning of period\n\n \n\n \n\n21,361\n\n \n\n \n\n \n\n13,359\n\n \n\n \n\n \n\n37,358\n\n \n\nCash, cash equivalents, and restricted cash, end of period\n\n \n\n$\n\n20,600\n\n \n\n \n\n$\n\n21,361\n\n \n\n \n\n$\n\n13,359\n\n \n\nSupplemental disclosure of cash flow information:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCash paid for interest\n\n \n\n$\n\n8,521\n\n \n\n \n\n$\n\n9,295\n\n \n\n \n\n$\n\n9,210\n\n \n\nCash paid for income taxes\n\n \n\n \n\n301\n\n \n\n \n\n \n\n356\n\n \n\n \n\n \n\n322\n\n \n\nSee accompanying Notes to Consolidated Financial Statements.\n\n \n\n94\n\n \n\nCERUS CORPORATION\n\nNOTES TO CONSOLIDATED FINANCIAL STATEMENTS\n\n \n\nNote 1. Nature of Operations and Basis of Presentation\n\nCerus Corporation (the “Company”) was incorporated in September 1991 and is developing and commercializing the INTERCEPT Blood System, which is designed to enhance the safety of blood components through pathogen reduction. The Company has worldwide commercialization rights for the INTERCEPT Blood System for platelets, plasma, red blood cells, and cryoprecipitation.\n\nThe Company sells its INTERCEPT platelet and plasma systems in North America, Europe, Middle East and Africa, and other regions around the world. Also in the United States (“U.S.”), the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The Company conducts significant research, development, testing and regulatory compliance activities on its product candidates that, together with anticipated selling, general and administrative expenses, are expected to result in substantial additional losses, and the Company may need to adjust its operating plans and programs based on the availability of cash resources.\n\n \n\nNote 2. Summary of Significant Accounting Policies\n\nPrinciples of Consolidation\n\nThe accompanying consolidated financial statements include those of Cerus Corporation, its subsidiary, and its variable interest entity in which the Company is the primary beneficiary in accordance with the consolidation accounting guidance, after elimination of all intercompany accounts and transactions (together with Cerus Corporation, hereinafter “Cerus” or the “Company”). These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).\n\nReclassifications\n\nCertain items related to the categorization of product revenue by geographical location in the prior period have been reclassified to conform to the current period presentation. These reclassifications did not have any effect on prior year total revenue, net loss, or shareholders’ equity.\n\nUse of Estimates\n\nThe preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, the collectability of accounts receivable, inventory classification and related reserves, fair values of investments, the allowance for credit losses of available-for-sale securities and accounts receivable, stock-based compensation, goodwill, useful lives of property and equipment, income taxes, and incremental borrowing rate, among others. The Company bases its estimates on historical experience, future projections, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.\n\nRevenue\n\nRevenue is recognized by applying the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.\n\nThe Company’s main source of revenue is product revenue from sales of the INTERCEPT Blood System for platelets and plasma (“platelet and plasma systems” or “disposable kits”), UVA illumination devices (“illuminators”), INTERCEPT Fibrinogen Complex (“IFC”), spare parts and storage solutions, and maintenance services of illuminators. The Company sells its platelet and plasma systems directly to blood banks, hospitals, universities, government agencies, as well as to distributors in certain regions. The Company sells its IFC primarily to hospitals and blood banks. The Company uses a binding purchase order or signed sales contract as evidence of a contract and satisfaction of its policy. Generally, the Company’s sales contracts for disposable kits and illuminators with its customers do not provide for open return rights, except within a reasonable time after receipt of goods in the case of defective or non-conforming product. The contracts with customers can include various combinations of products, and to a lesser extent, services. The Company must determine whether products or services are capable of being distinct and accounted for as separate performance obligations, or are accounted for as a combined performance obligation. The Company must allocate the transaction price to each performance obligation on a relative SSP basis and recognize the product revenue when the performance obligation is satisfied. The Company determines the SSP by using the historical selling price of the products and services. If the amount of consideration in a contract is variable, the Company\n\n95\n\n \n\nestimates the amount of variable consideration that should be included in the transaction price using the most likely amount method, to the extent it is probable that a significant future reversal of cumulative product revenue under the contract will not occur. Product revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to receive in exchange for those products or services. Product revenue from the sale of illuminators, disposable kits, IFC, spare parts and storage solutions are recognized upon the transfer of control of the products to the customer. Product revenue from maintenance services are recognized ratably on a straight-line basis over the term of maintenance as customers simultaneously consume and receive benefits. Freight costs charged to customers are recorded as a component of product revenue. Taxes that the Company invoices to its customers and remits to governments are recorded on a net basis, which excludes such tax from product revenue.\n\nThe Company receives funding under its U.S. government contracts that support research and development of defined projects. The Biomedical Advanced Research and Development Authority (“BARDA”) and the U.S. Food and Drug Administration (“FDA”) contracts generally provide for reimbursement of approved costs incurred under the terms of the contracts. Revenue related to the cost reimbursement provisions is recognized as the qualified direct and indirect costs on the projects are incurred. The Department of Defense (“DoD”) contract provides for payments upon completion of each milestone. Revenue from the DoD contract is recognized on the application of the cost-to-cost input method, which measures the extent of progress towards completion of its single performance obligation based on the ratio of actual costs incurred to the total estimated costs over the performance period of the agreement. Revenue is recorded as a percentage of the transaction price based on the extent of progress towards completion. The Company invoices under its U.S. government contracts using the provisional rates in the government contracts and thus is subject to future audits at the discretion of the government. The Company believes that government contract revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement. However, these audits could result in an adjustment to government contract revenue previously reported, which adjustments could be potentially significant. Costs incurred related to services performed under the contracts are included as a component of research and development or selling, general and administrative expenses in the Company’s consolidated statements of operations. The Company’s use of estimates in recording accrued liabilities for government contract activities (see “Use of Estimates” above) affects the revenue recorded from development funding and under the government contracts.\n\nDisaggregation of Product Revenue\n\nProduct revenue by geographical locations of customers during the years ended December 31, 2025, 2024 and 2023, was as follows (in thousands):\n\n \n\nYear Ended December 31,\n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nProduct revenue:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nNorth America\n\n \n\n$\n\n135,875\n\n \n\n \n\n$\n\n119,978\n\n \n\n \n\n$\n\n98,550\n\n \n\nEurope, Middle East and Africa\n\n \n\n \n\n67,370\n\n \n\n \n\n \n\n56,327\n\n \n\n \n\n \n\n55,008\n\n \n\nOther\n\n \n\n \n\n2,888\n\n \n\n \n\n \n\n3,965\n\n \n\n \n\n \n\n2,809\n\n \n\nTotal product revenue\n\n \n\n$\n\n206,133\n\n \n\n \n\n$\n\n180,270\n\n \n\n \n\n$\n\n156,367\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nContract Balances\n\nThe Company invoices its customers based upon the terms in the contracts, which generally require payment 30 to 60 days from the date of invoice. Accounts receivable are recorded when the Company’s right to the consideration is estimated to be unconditional. The Company’s conditional rights to the consideration are recorded as contract assets. As of December 31, 2025 and December 31, 2024, the Company had $0.4 million and zero, respectively, of contract assets related to DoD included within “Prepaid and other current assets” on the Company’s consolidated balance sheets.\n\nContract liabilities mainly consist of deferred revenue related to maintenance services, unshipped products, and uninstalled illuminators, or receivables from customers that are not yet recognized as revenue. Maintenance services are generally billed upfront at the beginning of each annual service period and recognized ratably over the contractual service period. The Company applies an optional exemption to not disclose the value of unsatisfied performance obligations for contracts that have an original expected duration of one year or less. As of December 31, 2025 and December 31, 2024, the Company had zero and $0.5 million, respectively, of contract liabilities related to the DoD included within “Deferred revenue” on the Company’s consolidated balance sheets.\n\nResearch and Development Expenses\n\nResearch and development (“R&D”) expenses are charged to expense when incurred, including cost incurred pursuant to the terms of the Company’s U.S. government contracts. R&D expenses include salaries and related expenses for scientific and regulatory personnel, non-cash stock-based compensation, payments to consultants, supplies and chemicals used in in-house laboratories, costs of R&D facilities, depreciation of equipment and external contract research expenses, including clinical trials, preclinical safety studies, other laboratory studies, process development and product manufacturing for research use.\n\n96\n\n \n\nThe Company’s use of estimates in recording accrued liabilities for R&D activities (see “Use of Estimates” above) affects the amounts of R&D expenses recorded from development funding. Actual results may differ from those estimates under different assumptions or conditions.\n\nCash Equivalents\n\nThe Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. These investments primarily consist of money market instruments and are classified as available-for-sale.\n\nInvestments\n\nInvestments with original maturities of greater than three months primarily include corporate debt and U.S. government agency securities that are designated as available-for-sale and classified as short-term investments. Available-for-sale securities are carried at estimated fair value. The Company views its available-for-sale portfolio as available for use in its current operations. Unrealized gains and losses derived by changes in the estimated fair value of available-for-sale securities are recorded in “Unrealized gains (losses) on available-for-sale investments, net of taxes” on the Company’s consolidated statements of comprehensive loss. Realized gains (losses) from the sale of available-for-sale investments, if any, are determined on a specific identification method, and are recorded in “Other income (expense), net” on the Company’s consolidated statements of operations. The costs of securities sold are based on the specific identification method, if applicable. The Company reported the amortization of any premium and accretion of any discount resulting from the purchase of debt securities as a component of interest income.\n\nThe Company also reviews its available-for-sale securities on a regular basis to evaluate whether any security in an unrealized loss position has expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. Expected credit losses, if any, are recorded in “Other income (expense), net” on the Company’s consolidated statements of operations.\n\nDeferred Compensation Plan\n\nThe Company’s deferred compensation plan, pursuant to which compensation deferrals began in 2020, is a nonqualified deferred compensation plan that allows highly compensated employees to defer up to 80 percent of their base salary and up to 100 percent of their variable compensation each plan year. The Company may make discretionary contributions to each participant in an amount determined each year. To fund the deferred compensation plan’s long-term liability, the Company purchases Company-owned life insurance contracts on certain employees. The insurance serves as an investment source for the funds being set aside. Participants in the deferred compensation plan select the mutual funds in which their compensation deferrals are deemed to be invested as a component of the insurance contracts. As of December 31, 2025 and December 31, 2024, $3.2 million and $2.8 million, respectively, were included in “Other assets” on the Company’s consolidated balance sheets, which represents the cash surrender value of the associated life insurance policies. As of December 31, 2025 and December 31, 2024, $3.8 million and $3.1 million, respectively, were included in “Other non-current liabilities”, and $0.2 million and $0.2 million, respectively, were included in “Accrued liabilities” on the Company’s consolidated balance sheets, which represent the carrying value of the liability for deferred compensation. Gains and losses on the investments related to the nonqualified deferred compensation plan are included in “Other income (expense), net”, on the Company’s consolidated statements of operations, and corresponding changes in their deferred compensation liability are included in operating expenses.\n\nRestricted Cash\n\nAs of December 31, 2025 and December 31, 2024, the Company’s “Restricted cash” consisted primarily of a letter of credit relating to an office building lease. As of December 31, 2025 and December 31, 2024, the Company also had certain non-U.S. dollar denominated deposits recorded as “Restricted cash” in compliance with certain foreign contractual requirements.\n\nConcentration of Credit Risk\n\nFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, available-for-sale securities and accounts receivable.\n\nPursuant to the Company’s investment policy, substantially all of the Company’s cash, cash equivalents and available-for-sale securities are maintained at major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company’s investments carry high credit quality ratings, which is in accordance with its investment policy. At December 31, 2025, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company’s cash equivalents and short-term investments.\n\nOn a regular basis, including at the time of sale, the Company performs credit evaluations of its significant customers that it expects to sell to on credit terms. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines credit losses may occur, the Company maintains an allowance for estimated credit losses on its\n\n97\n\n \n\nconsolidated balance sheets and records a charge on its consolidated statements of operations as a component of selling, general and administrative expenses.\n\nThe Company had three and one customer(s) that accounted for more than 10% of the Company’s outstanding accounts receivable at December 31, 2025 and December 31, 2024, respectively. These customers cumulatively represented approximately 50% and 37% of the Company’s outstanding accounts receivable at December 31, 2025 and December 31, 2024, respectively. To date, the Company has not experienced collection difficulties from these customers.\n\nInventories\n\nAt December 31, 2025 and December 31, 2024, inventory consisted of raw materials, work-in-process and finished goods. Finished goods include INTERCEPT disposable kits, illuminators, and certain components for the illuminators. Platelet and plasma systems’ disposable kits generally expire no later than 24 months from the date of manufacture. However, in the fourth quarter of 2024, the Company received FDA approval for an 18-month shelf life for our platelet kits. Illuminators and individual components do not have regulated expiration dates. Raw materials and work-in-process includes certain components that are manufactured over a protracted length of time before being ultimately incorporated and assembled by Fresenius, Inc. (with their affiliates, “Fresenius”) into the finished INTERCEPT disposable kits. It is not customary for the Company’s production cycle for inventory to exceed 12 months, however, in certain circumstances the Company purchases inventory components it expects to consume beyond 12 months. The Company uses its best judgment to factor in lead times for the production of its raw materials, work-in-process and finished units to meet the Company’s forecasted demands. Additionally, from time-to-time, the Company may engage in strategic longer-range inventory purchases due to concentration of supplier risk, obsolescence of materials or components, or simply as safety stock to mitigate disruption to supply. Based upon estimated production needs and current inventory levels, the Company determines the amount of inventory necessary for the next 12 months. Any amounts in excess of this 12 month rolling projection are classified as “Non-current inventories” in the consolidated balance sheets. Changes to those estimates could potentially impact amounts recorded as current or non-current assets.\n\nInventory is recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. The Company writes down specifically identified unusable, obsolete, slow-moving, or known unsalable inventory that has no alternative use in the period that it is first recognized by using a number of factors including product expiration dates, open and unfulfilled orders, and sales forecasts. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded within “Cost of product revenue” on the Company’s consolidated statements of operations. At December 31, 2025 and December 31, 2024, the Company had $0.6 million and $0.9 million, respectively, for potential obsolete, expiring or unsalable product.\n\nProperty and Equipment, net\n\nProperty and equipment is comprised of furniture, equipment, leasehold improvements, construction-in-progress, information technology hardware and software and is recorded at cost. At the time the property and equipment is ready for its intended use, it is depreciated on a straight-line basis over the estimated useful lives of the assets (generally three to five years). Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or the estimated useful lives of the improvements. During the years ended December 31, 2025, 2024 and 2023, the Company had non-cash purchases of capital expenditures of $0.6 million, less than $0.1 million and $0.8 million, respectively.\n\nGoodwill\n\nGoodwill is not amortized, but instead is subject to an impairment test performed on an annual basis, or more frequently if events or changes in circumstances indicate that goodwill may be impaired. Such impairment analysis is performed on August 31 of each year, or more frequently if indicators of impairment exist. The test for goodwill impairment may be assessed using qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than the carrying amount, the Company must then proceed with performing the quantitative goodwill impairment test. The Company may choose not to perform the qualitative assessment to test goodwill for impairment and proceed directly to the quantitative impairment test; however, the Company may revert to the qualitative assessment to test goodwill for impairment in any subsequent period. The quantitative goodwill impairment test compares the fair value of each reporting unit with its respective carrying amount, including goodwill. The Company has determined that it operates as one reporting unit and estimates the fair value of its one reporting unit using the enterprise approach under which it considers the quoted market capitalization of the Company as reported on the Nasdaq Global Market. The Company considers quoted market prices that are available in active markets to be the best evidence of fair value. The Company also considers other factors, which include future forecasted results, the economic environment and overall market conditions. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess, limited to the carrying amount of goodwill in the Company’s one reporting unit.\n\n98\n\n \n\nDuring the years ended December 31, 2025, 2024 and 2023, the Company did not dispose of, impair or recognize additional goodwill.\n\nLong-lived Assets\n\nThe Company evaluates its long-lived assets for impairment by continually monitoring events and changes in circumstances that could indicate carrying amounts of its long-lived assets may not be recoverable. When such events or changes in circumstances occur, the Company assesses recoverability by determining whether the carrying value of such assets will be recovered through the undiscounted expected future cash flows. If the expected undiscounted future cash flows are less than the carrying amount of these assets, the Company then measures the amount of the impairment loss based on the excess of the carrying amount over the fair value of the assets.\n\nForeign Currency\n\nThe functional currency of the Company’s Cerus Europe B.V. subsidiary is the U.S. dollar. Monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using the exchange rates at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are remeasured in U.S. dollars using historical exchange rates. Product revenues and expenses are remeasured using average exchange rates prevailing during the period. Remeasurements are recorded in “Foreign exchange loss” on the Company’s consolidated statements of operations.\n\nThe functional currency of the JV (as defined below) is the Chinese Renminbi. Monetary assets and liabilities denominated in foreign currencies are remeasured in Renminbi using the exchange rates at the balance sheet date. The financial statements of JV are translated into U.S. dollar for consolidation. The JV’s balance sheet is translated using the month-end exchange rate, and the JV’s income statement is translated using the monthly average exchange rate, the difference is recognized as cumulative translation adjustment.\n\nStock-Based Compensation\n\nStock-based compensation expense is measured at the grant-date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures. To the extent that stock awards contain performance criteria for vesting, stock-based compensation is recognized once the performance criteria are probable of being achieved.\n\nSee Note 12, Stock-Based Compensation, for further information regarding the Company’s stock-based compensation assumptions and expenses.\n\nConsolidated Variable Interest Entity\n\nIn February 2021, the Company entered into an Equity Joint Venture Contract with Shandong Zhongbaokang Medical Implements Co., Ltd. (“ZBK”), to establish Cerus Zhongbaokang (Shandong) Biomedical Co., LTD. (the “JV”) for the purpose of developing, obtaining regulatory approval for, and eventual manufacturing and commercialization of the INTERCEPT blood transfusion for platelets and red blood cells in the People’s Republic of China. The Company owns 51% of equity in the JV and consolidates the JV as it has determined that the investment is a variable interest entity and that the Company is the primary beneficiary.\n\nOperating expenses for the JV were de minimis for all periods presented.\n\nIncome Taxes\n\nThe provision for income taxes is accounted for using an asset and liability approach, under which deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not recognize tax positions that do not have a greater than 50% likelihood of being recognized upon review by a taxing authority having full knowledge of all relevant information. Use of a valuation allowance is not an appropriate substitute for derecognition of a tax position. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. Although the Company believes it more likely than not that a taxing authority would agree with its current tax positions, there can be no assurance that the tax positions the Company has taken will be substantiated by a taxing authority if reviewed. The Company’s U.S. federal tax returns filed for years 2005 through 2024, and California tax returns filed for years through 2024, remain subject to examination by the taxing jurisdictions due to unutilized net operating losses and research credits. The Company continues to carry a valuation allowance on substantially all of its net deferred tax assets.\n\nNet Loss Per Share Attributable to Cerus Corporation\n\nBasic net loss per share attributable to Cerus Corporation is computed by dividing net loss attributable to Cerus Corporation by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to Cerus Corporation gives effect to all potentially dilutive common shares outstanding for the period. The potentially dilutive securities include stock options, employee stock purchase plan rights and restricted stock units, which are calculated using the treasury stock method. For the years ended December 31, 2025, 2024 and 2023, all potentially dilutive securities outstanding have been excluded from the computation of dilutive weighted average shares outstanding because such securities have an antidilutive impact due to losses reported.\n\n99\n\n \n\nThe following table sets forth the reconciliation of the numerator and denominator used in the computation of basic and diluted net loss per share for the years ended December 31, 2025, 2024 and 2023 (in thousands, except per share amounts):\n\n \n\n \n\n \n\nYear Ended December 31,\n\n \n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\n \n\nNumerator for Basic and Diluted:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nNet loss attributable to Cerus Corporation\n\n \n\n$\n\n(15,627\n\n)\n\n \n\n$\n\n(20,918\n\n)\n\n \n\n$\n\n(37,489\n\n)\n\n \n\nDenominator:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBasic weighted average number of shares outstanding\n\n \n\n \n\n190,594\n\n \n\n \n\n \n\n184,563\n\n \n\n \n\n \n\n180,270\n\n \n\n \n\nEffect of dilutive potential shares\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\nDiluted weighted average number of shares outstanding\n\n \n\n \n\n190,594\n\n \n\n \n\n \n\n184,563\n\n \n\n \n\n \n\n180,270\n\n \n\n \n\nNet loss per share attributable to Cerus Corporation:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBasic and diluted\n\n \n\n$\n\n(0.08\n\n)\n\n \n\n$\n\n(0.11\n\n)\n\n \n\n$\n\n(0.21\n\n)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nThe table below presents potential shares that were excluded from the calculation of the weighted average number of shares outstanding used for the calculation of diluted net loss per share. These are excluded from the calculation due to their anti-dilutive effect for the years ended December 31, 2025, 2024 and 2023 (shares in thousands):\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nYear Ended December 31,\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nWeighted average number of anti-dilutive potential shares:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nStock options\n\n \n\n \n\n10,738\n\n \n\n \n\n \n\n12,993\n\n \n\n \n\n \n\n14,896\n\n \n\nRestricted stock units\n\n \n\n \n\n18,608\n\n \n\n \n\n \n\n13,880\n\n \n\n \n\n \n\n10,192\n\n \n\nEmployee stock purchase plan rights\n\n \n\n \n\n300\n\n \n\n \n\n \n\n349\n\n \n\n \n\n \n\n396\n\n \n\n            Total\n\n \n\n \n\n29,646\n\n \n\n \n\n \n\n27,222\n\n \n\n \n\n \n\n25,484\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nLeases\n\nThe Company determines if an arrangement is a lease at inception. Operating leases are included in “Operating lease right-of-use assets”, “Operating lease liabilities – current” and “Operating lease liabilities – non-current” in the Company’s consolidated balance sheets. As of December 31, 2025 and December 31, 2024, the Company did not have finance leases.\n\nOperating lease right-of-use assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease right-of-use assets also include any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when the options are reasonably certain to be exercised. Operating leases are recognized on a straight-line basis over the lease term.\n\nGuarantee and Indemnification Arrangements\n\nThe Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company’s technology infringes the intellectual property rights of a third-party or claims that the sale or use of the Company’s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.\n\nThe Company generally provides for a one-year warranty on certain of its disposable kits and illuminators covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. The Company has not experienced significant or systemic warranty claims nor is it aware of any existing current warranty claims. Accordingly, the Company had not accrued for any future warranty costs for its products at December 31, 2025 and December 31, 2024.\n\nFair Value of Financial Instruments\n\nThe Company applies the provisions of fair value relating to its financial assets and liabilities. The carrying amounts of accounts receivables, accounts payable, and other accrued liabilities approximate their fair value due to the relative short-term maturities. Based\n\n100\n\n \n\non the borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of its debt approximates their carrying amounts. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis, including its available-for-sale securities. The Company classifies instruments within Level 1 if quoted prices are available in active markets for identical assets, which include the Company’s cash accounts and money market funds. The Company classifies instruments in Level 2 if the instruments are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. These instruments include the Company’s corporate debt and U.S. government agency securities holdings. The available-for-sale securities are held by a custodian who obtains investment prices from a third-party pricing provider that uses standard inputs (observable in the market) to models which vary by asset class. The Company classifies instruments in Level 3 if one or more significant inputs or significant value drivers are unobservable. The Company assesses any transfers among fair value measurement levels at the end of each reporting period.\n\nSee Note 3, Available-for-sale Securities and Fair Value on Financial Instruments, for further information regarding the Company’s valuation of financial instruments.\n\nNew Accounting Pronouncements\n\nRecently adopted accounting pronouncements\n\nIn December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis, with the option to apply it retrospectively, for annual periods beginning after December 15, 2024. The Company adopted the new accounting standard on a prospective basis effective January 1, 2025. The adoption of this ASU had no material impact on the Company’s consolidated financial statements.\n\n \n\n101\n\n \n\nRecently issued accounting pronouncements not yet adopted\n\nIn November 2024, the FASB issued ASU 2024-03, Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective for the Company’s annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on the Company’s related disclosures.\n\nIn December 2025, the FASB issued ASU 2025-10, Accounting for Government Grants Received by Business Entities, to establish guidance on the recognition, measurement, and presentation of government grants received by business entities. The new guidance leverages the principles in the accounting framework for government assistance in IFRS, specifically IAS 20, Accounting for Government Grants and Disclosure of Government Assistance; makes certain targeted improvements; and modifies certain of the existing disclosure requirements in ASC 832, Government Assistance. The new guidance is effective for the Company’s annual periods beginning after December 15, 2028, including interim periods within, with early adoption permitted. The guidance can be applied on a modified prospective basis, a modified retrospective basis, or a full retrospective basis. The Company is currently in the process of evaluating the impact of this pronouncement on the Company’s related disclosures.\n\nIn December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (ASU 2025-11), to clarify interim disclosure requirements and the applicability of Topic 270. The guidance will be effective for interim periods beginning January 1, 2028. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently in the process of evaluating the impact of this pronouncement on the Company’s related disclosures.\n\nThe Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company’s Consolidated Financial Statements.\n\n \n\n \n\nNote 3. Available-for-sale Securities and Fair Value on Financial Instruments\n\nAvailable-for-sale Securities\n\nThe following is a summary of available-for-sale securities at December 31, 2025 (in thousands):\n\n \n\n \n\n \n\nDecember 31, 2025\n\n \n\n \n\n \n\nAmortized\nCost\n\n \n\n \n\nGross\nUnrealized Gain\n\n \n\n \n\nGross\nUnrealized Loss\n\n \n\n \n\nFair Value\n\n \n\nMoney market funds\n\n \n\n$\n\n1,810\n\n \n\n \n\n$\n\n—\n\n \n\n \n\n$\n\n—\n\n \n\n \n\n$\n\n1,810\n\n \n\nUnited States government agency securities\n\n \n\n \n\n23,431\n\n \n\n \n\n \n\n49\n\n \n\n \n\n \n\n(1\n\n)\n\n \n\n \n\n23,479\n\n \n\nCorporate debt securities\n\n \n\n \n\n36,768\n\n \n\n \n\n \n\n55\n\n \n\n \n\n \n\n(1\n\n)\n\n \n\n \n\n36,822\n\n \n\nMortgage-backed securities\n\n \n\n \n\n2,795\n\n \n\n \n\n \n\n7\n\n \n\n \n\n \n\n(185\n\n)\n\n \n\n \n\n2,617\n\n \n\nTotal available-for-sale securities\n\n \n\n$\n\n64,804\n\n \n\n \n\n$\n\n111\n\n \n\n \n\n$\n\n(187\n\n)\n\n \n\n$\n\n64,728\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nThe following is a summary of available-for-sale securities at December 31, 2024 (in thousands):\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDecember 31, 2024\n\n \n\n \n\n \n\nAmortized\nCost\n\n \n\n \n\nGross\nUnrealized Gain\n\n \n\n \n\nGross\nUnrealized Loss\n\n \n\n \n\nFair Value\n\n \n\nMoney market funds\n\n \n\n$\n\n1,773\n\n \n\n \n\n$\n\n—\n\n \n\n \n\n$\n\n—\n\n \n\n \n\n$\n\n1,773\n\n \n\nUnited States government agency securities\n\n \n\n \n\n24,060\n\n \n\n \n\n \n\n54\n\n \n\n \n\n \n\n(52\n\n)\n\n \n\n \n\n24,062\n\n \n\nCorporate debt securities\n\n \n\n \n\n33,357\n\n \n\n \n\n \n\n53\n\n \n\n \n\n(39\n\n)\n\n \n\n \n\n33,371\n\n \n\nMortgage-backed securities\n\n \n\n \n\n3,070\n\n \n\n \n\n \n\n—\n\n \n\n \n\n(317\n\n)\n\n \n\n \n\n2,753\n\n \n\nTotal available-for-sale securities\n\n \n\n$\n\n62,260\n\n \n\n \n\n$\n\n107\n\n \n\n \n\n$\n\n(408\n\n)\n\n \n\n$\n\n61,959\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n102\n\n \n\n \n\nAvailable-for-sale securities at December 31, 2025 and December 31, 2024, consisted of the following by contractual maturity (in thousands):\n\n \n\n \n\nDecember 31, 2025\n\n \n\n \n\nDecember 31, 2024\n\n \n\n \n\n \n\nAmortized Cost\n\n \n\n \n\nFair Value\n\n \n\n \n\nAmortized Cost\n\n \n\n \n\nFair Value\n\n \n\nOne year or less\n\n \n\n$\n\n46,128\n\n \n\n \n\n$\n\n46,209\n\n \n\n \n\n$\n\n38,174\n\n \n\n \n\n$\n\n38,173\n\n \n\nGreater than one year and less than five years\n\n \n\n \n\n18,676\n\n \n\n \n\n \n\n18,519\n\n \n\n \n\n \n\n24,086\n\n \n\n \n\n \n\n23,786\n\n \n\nTotal available-for-sale securities\n\n \n\n$\n\n64,804\n\n \n\n \n\n$\n\n64,728\n\n \n\n \n\n$\n\n62,260\n\n \n\n \n\n$\n\n61,959\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nThe following tables show all available-for-sale marketable securities in an unrealized loss position for which an allowance for credit losses has not been recognized and the related gross unrealized losses and fair value, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position (in thousands):\n\n \n\n \n\nDecember 31, 2025\n\n \n\n \n\nLess than 12 Months\n\n \n\n \n\n12 Months or Greater\n\n \n\n \n\nTotal\n\n \n\n \n\nFair Value\n\n \n\n \n\nUnrealized Loss\n\n \n\n \n\nFair Value\n\n \n\n \n\nUnrealized Loss\n\n \n\n \n\nFair Value\n\n \n\n \n\nUnrealized Loss\n\n \n\nCorporate debt securities\n\n$\n\n3,203\n\n \n\n \n\n$\n\n(1\n\n)\n\n \n\n$\n\n—\n\n \n\n \n\n$\n\n—\n\n \n\n$\n\n3,203\n\n \n\n$\n\n(1\n\n)\n\nUnited States government agency securities\n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n260\n\n \n\n \n\n \n\n(1\n\n)\n\n \n\n260\n\n \n\n \n\n(1\n\n)\n\nMortgage-backed securities\n\n \n\n214\n\n \n\n \n\n \n\n(1\n\n)\n\n \n\n \n\n2,219\n\n \n\n \n\n \n\n(184\n\n)\n\n \n\n2,433\n\n \n\n \n\n(185\n\n)\n\n    Total\n\n$\n\n3,417\n\n \n\n$\n\n(2\n\n)\n\n$\n\n2,479\n\n \n\n$\n\n(185\n\n)\n\n$\n\n5,896\n\n \n\n$\n\n(187\n\n)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDecember 31, 2024\n\n \n\n \n\nLess than 12 Months\n\n \n\n \n\n12 Months or Greater\n\n \n\n \n\nTotal\n\n \n\n \n\nFair Value\n\n \n\n \n\nUnrealized Loss\n\n \n\n \n\nFair Value\n\n \n\n \n\nUnrealized Loss\n\n \n\n \n\nFair Value\n\n \n\n \n\nUnrealized Loss\n\n \n\nCorporate debt securities\n\n$\n\n14,002\n\n \n\n$\n\n(27\n\n)\n\n$\n\n3,967\n\n \n\n$\n\n(12\n\n)\n\n$\n\n17,969\n\n \n\n$\n\n(39\n\n)\n\nUnited States government agency securities\n\n \n\n8,468\n\n \n\n \n\n(37\n\n)\n\n \n\n3,279\n\n \n\n \n\n(15\n\n)\n\n \n\n11,747\n\n \n\n \n\n(52\n\n)\n\nMortgage-backed securities\n\n \n\n402\n\n \n\n \n\n(10\n\n)\n\n \n\n2,351\n\n \n\n \n\n(307\n\n)\n\n \n\n2,753\n\n \n\n \n\n(317\n\n)\n\n    Total\n\n$\n\n22,872\n\n \n\n$\n\n(74\n\n)\n\n$\n\n9,597\n\n \n\n$\n\n(334\n\n)\n\n$\n\n32,469\n\n \n\n$\n\n(408\n\n)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nThe Company typically invests in highly-rated securities, and its investment policy limits the amount of credit exposure to any one issuer. The policy generally requires investments to be investment grade, with the primary objective of minimizing the potential risk of principal loss. Fair values were determined for each individual security in the investment portfolio. When evaluating an investment for expected credit losses, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and the Company’s intent to sell, or whether it is more likely than not it will be required to sell, the investment before recovery of the investment’s cost basis. The Company also regularly reviews its investments in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. During the years ended December 31, 2025, 2024 and 2023, the Company did not recognize any expected credit losses. The Company has no current requirement or intent to sell the securities in an unrealized loss position. The Company expects to recover up to (or beyond) the initial cost of investment for securities held.\n\n \n\nThe Company recorded less than $0.1 million of gross realized gains from the sale or maturity of available-for-sale investments during the years ended December 31, 2025, 2024 and 2023, respectively. The Company recorded less than $0.1 million of gross realized losses from the sale or maturity of available-for-sale investments during the years ended December 31, 2025, 2024 and 2023, respectively.\n\nFair Value Disclosures\n\nThe Company uses certain assumptions that market participants would use to determine the fair value of an asset or liability in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:\n\n•\nLevel 1: Quoted prices in active markets for identical instruments\n\n103\n\n \n\n•\nLevel 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)\n\n•\nLevel 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)\n\nMoney market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.\n\nTo estimate the fair value of Level 2 debt securities as of December 31, 2025, the Company’s primary pricing service relies on inputs from multiple industry-recognized pricing sources to determine the price for each investment. Corporate debt and U.S. government agency securities are systematically priced by this service as of the close of business each business day. If the primary pricing service does not price a specific asset a secondary pricing service is utilized.\n\nThe fair values of the Company’s financial assets and liabilities were determined using the following inputs at December 31, 2025 (in thousands):\n\n \n\n \n\nBalance sheet\n\n \n\n \n\n \n\n \n\nQuoted\nPrices in\nActive\nMarkets for Identical\nAssets\n\n \n\n \n\nSignificant\nOther\nObservable\nInputs\n\n \n\n \n\nSignificant Unobservable Inputs\n\n \n\n \n\n \n\nclassification\n\n \n\nTotal\n\n \n\n \n\n(Level 1)\n\n \n\n \n\n(Level 2)\n\n \n\n \n\n(Level 3)\n\n \n\nMoney market funds\n\n \n\nCash and cash equivalents\n\n \n\n$\n\n1,810\n\n \n\n \n\n$\n\n1,810\n\n \n\n \n\n$\n\n—\n\n \n\n \n\n$\n\n—\n\n \n\nUnited States government agency securities\n\n \n\nShort-term investments\n\n \n\n \n\n23,479\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n23,479\n\n \n\n \n\n \n\n—\n\n \n\nCorporate debt securities\n\n \n\nShort-term investments\n\n \n\n \n\n36,822\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n36,822\n\n \n\n \n\n \n\n—\n\n \n\nMortgage-backed securities\n\n \n\nShort-term investments\n\n \n\n \n\n2,617\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n2,617\n\n \n\n \n\n \n\n—\n\n \n\nTotal short-term investments\n\n \n\n \n\n \n\n$\n\n64,728\n\n \n\n \n\n$\n\n1,810\n\n \n\n \n\n$\n\n62,918\n\n \n\n \n\n$\n\n—\n\n \n\n \n\nThe fair values of the Company’s financial assets and liabilities were determined using the following inputs at December 31, 2024 (in thousands):\n\n \n\n \n\nBalance sheet\n\n \n\n \n\n \n\n \n\nQuoted\nPrices in\nActive\nMarkets for Identical\nAssets\n\n \n\n \n\nSignificant\nOther\nObservable\nInputs\n\n \n\n \n\nSignificant Unobservable Inputs\n\n \n\n \n\n \n\nclassification\n\n \n\nTotal\n\n \n\n \n\n(Level 1)\n\n \n\n \n\n(Level 2)\n\n \n\n \n\n(Level 3)\n\n \n\nMoney market funds\n\n \n\nCash and cash equivalents\n\n \n\n$\n\n1,773\n\n \n\n \n\n$\n\n1,773\n\n \n\n \n\n$\n\n—\n\n \n\n \n\n$\n\n—\n\n \n\nUnited States government agency securities\n\n \n\nShort-term investments\n\n \n\n \n\n24,062\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n24,062\n\n \n\n \n\n \n\n—\n\n \n\nCorporate debt securities\n\n \n\nShort-term investments\n\n \n\n \n\n33,371\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n33,371\n\n \n\n \n\n \n\n—\n\n \n\nMortgage-backed securities\n\n \n\nShort-term investments\n\n \n\n \n\n2,753\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n2,753\n\n \n\n \n\n \n\n—\n\n \n\nTotal short-term investments\n\n \n\n \n\n \n\n$\n\n61,959\n\n \n\n \n\n$\n\n1,773\n\n \n\n \n\n$\n\n60,186\n\n \n\n \n\n$\n\n—\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nThe Company did not have any transfers among fair value measurement levels during the years ended December 31, 2025 and December 31, 2024.\n\n \n\n \n\nNote 4. Inventories\n\nInventories at December 31, 2025 and December 31, 2024, consisted of the following (in thousands):\n\n \n\n \n\nDecember 31, 2025\n\n \n\n \n\nDecember 31, 2024\n\n \n\nRaw materials\n\n \n\n$\n\n8,499\n\n \n\n \n\n$\n\n8,641\n\n \n\nWork-in-process\n\n \n\n \n\n22,687\n\n \n\n \n\n \n\n22,522\n\n \n\nFinished goods\n\n \n\n \n\n40,058\n\n \n\n \n\n \n\n21,132\n\n \n\nTotal inventories\n\n \n\n \n\n71,244\n\n \n\n \n\n \n\n52,295\n\n \n\nLess: non-current inventories\n\n \n\n \n\n15,143\n\n \n\n \n\n \n\n14,145\n\n \n\nTotal current inventories\n\n \n\n$\n\n56,101\n\n \n\n \n\n$\n\n38,150\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nNon-current inventories primarily consists of raw materials and work-in-process.\n\n \n\n104\n\n \n\nNote 5. Property and Equipment, net\n\nProperty and equipment, net at December 31, 2025 and December 31, 2024, consisted of the following (in thousands):\n\n \n\n \n\n \n\nDecember 31,\n\n \n\n \n\n \n\n2025\n\n \n\n2024\n\n \n\nConstruction-in-progress\n\n \n\n$\n\n2,901\n\n \n\n \n\n$\n\n—\n\n \n\nMachinery and equipment\n\n \n\n \n\n6,387\n\n \n\n \n\n \n\n5,949\n\n \n\nComputer equipment and software\n\n \n\n \n\n3,593\n\n \n\n \n\n \n\n3,969\n\n \n\nFurniture and fixtures\n\n \n\n \n\n1,859\n\n \n\n \n\n \n\n2,008\n\n \n\nLeasehold improvements\n\n \n\n \n\n12,189\n\n \n\n \n\n \n\n12,192\n\n \n\nConsigned equipment\n\n \n\n \n\n1,948\n\n \n\n \n\n \n\n1,475\n\n \n\nTotal property and equipment, gross\n\n \n\n \n\n28,877\n\n \n\n \n\n \n\n25,593\n\n \n\nAccumulated depreciation and amortization\n\n \n\n \n\n(19,673\n\n)\n\n \n\n \n\n(18,439\n\n)\n\nTotal property and equipment, net\n\n \n\n$\n\n9,204\n\n \n\n \n\n$\n\n7,154\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDepreciation and amortization expense related to property and equipment, net was $2.0 million, $2.0 million and $2.4 million for the years ended December 31, 2025, 2024 and 2023, respectively. As part of the Company’s restructuring plan, $0.7 million was recognized as an impairment of long-lived assets for leasehold improvements and furniture and fixtures and was recorded within “Restructuring” on the Company’s consolidated statement of operations for the year ended December 31, 2023. No impairment charges were incurred for the years ended December 31, 2025 and 2024.\n\n \n\nNote 6. Accrued Liabilities\n\nAccrued liabilities at December 31, 2025 and December 31, 2024, consisted of the following (in thousands):\n\n \n\n \n\n \n\nDecember 31, 2025\n\n \n\n \n\nDecember 31, 2024\n\n \n\nAccrued compensation and related costs\n\n \n\n$\n\n18,261\n\n \n\n \n\n$\n\n11,939\n\n \n\nAccrued professional services\n\n \n\n \n\n3,610\n\n \n\n \n\n \n\n3,406\n\n \n\nOther accrued expenses\n\n \n\n \n\n3,400\n\n \n\n \n\n \n\n3,598\n\n \n\nTotal accrued liabilities\n\n \n\n$\n\n25,271\n\n \n\n \n\n$\n\n18,943\n\n \n\n \n\nNote 7. Restructuring\n\nIn June 2023, pursuant to the Board of Directors’ approval, the Company began implementing a restructuring plan to pursue greater efficiency and to realign its business and strategic priorities. This included a facilities consolidation strategy to cease use of a part of its corporate office building under its operating lease (see Note 10, Commitments and Contingencies) and reduction in force of its employee base. Affected employees received severance consideration and continuation of benefits, as well as transition assistance. During the year ended December 31, 2023, the Company recognized $3.7 million of restructuring charges related to severance cost and facilities consolidation. The Company substantially implemented the restructuring plan in 2023. The following is a summary of the Company’s accrued restructuring costs for one-time termination benefits, recorded within “Accrued liabilities” on the Company’s consolidated balance sheets (in thousands):\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nBalance at\n\n \n\n \n\nRestructuring\n\n \n\n \n\n \n\n \n\n \n\nBalance at\n\n \n\n \n\n \n\nDecember 31, 2024\n\n \n\n \n\nCharge\n\n \n\n \n\nCash Payments\n\n \n\n \n\nDecember 31, 2025\n\n \n\nOne-time termination benefits\n\n \n\n$\n\n—\n\n \n\n \n\n$\n\n—\n\n \n\n \n\n$\n\n—\n\n \n\n \n\n$\n\n—\n\n \n\nOther\n\n \n\n \n\n206\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n(26\n\n)\n\n \n\n \n\n180\n\n \n\nTotal\n\n \n\n$\n\n206\n\n \n\n \n\n$\n\n—\n\n \n\n \n\n$\n\n(26\n\n)\n\n \n\n$\n\n180\n\n \n\n \n\n105\n\n \n\nNote 8. Debt\n\nDebt at December 31, 2025, consisted of the following (in thousands):\n\n \n\n \n\nPrincipal\n\n \n\n \n\nUnamortized Discount\n\n \n\n \n\nNet Carrying\nValue\n\n \n\nTerm Loan\n\n \n\n$\n\n65,000\n\n \n\n \n\n$\n\n(80\n\n)\n\n \n\n$\n\n64,920\n\n \n\nRevolving Loan\n\n \n\n \n\n18,968\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n18,968\n\n \n\nTotal debt\n\n \n\n \n\n83,968\n\n \n\n \n\n(80\n\n)\n\n \n\n83,888\n\n \n\nLess: current portion\n\n \n\n \n\n43,343\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n43,343\n\n \n\nNon-current portion\n\n \n\n$\n\n40,625\n\n \n\n \n\n$\n\n(80\n\n)\n\n \n\n$\n\n40,545\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDebt at December 31, 2024, consisted of the following (in thousands):\n\n \n\n \n\n \n\nPrincipal\n\n \n\n \n\nUnamortized Discount\n\n \n\n \n\nNet Carrying\nValue\n\n \n\nTerm Loan\n\n \n\n$\n\n65,000\n\n \n\n \n\n$\n\n(138\n\n)\n\n \n\n$\n\n64,862\n\n \n\nRevolving Loan\n\n \n\n \n\n19,297\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n19,297\n\n \n\nTotal debt\n\n \n\n \n\n84,297\n\n \n\n \n\n \n\n(138\n\n)\n\n \n\n \n\n84,159\n\n \n\nLess: current portion\n\n \n\n \n\n19,297\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n19,297\n\n \n\nNon-current portion\n\n \n\n$\n\n65,000\n\n \n\n \n\n$\n\n(138\n\n)\n\n \n\n$\n\n64,862\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nPrincipal, interest and fee payments on the Term Loan Credit Agreement (as defined below) at December 31, 2025, are expected to be as follows (in thousands):\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nYear ended December 31,\n\n \n\nPrincipal\n\n \n\n \n\nInterest and Fees\n\n \n\n \n\nTotal\n\n \n\n2026\n\n \n\n$\n\n24,375\n\n \n\n \n\n$\n\n6,181\n\n \n\n \n\n$\n\n30,556\n\n \n\n2027\n\n \n\n \n\n32,500\n\n \n\n \n\n \n\n2,795\n\n \n\n \n\n \n\n35,295\n\n \n\n2028\n\n \n\n \n\n8,125\n\n \n\n \n\n \n\n1,448\n\n \n\n \n\n \n\n9,573\n\n \n\nTotal\n\n \n\n$\n\n65,000\n\n \n\n \n\n$\n\n10,424\n\n \n\n \n\n$\n\n75,424\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nLoan Agreements\n\n \n\nOn March 29, 2019, the Company entered into a Credit, Security and Guaranty Agreement (Term Loan) (the “Prior Term Loan Credit Agreement”) with MidCap Financial Trust (“MidCap”) to borrow up to $70 million in three tranches (collectively “Prior Term Loan”), with a maturity date of March 1, 2024. The first advance of $40.0 million (“Tranche 1”) was drawn by the Company on March 29, 2019, with the proceeds used in part to repay in full the outstanding term loans and fees under a prior loan agreement. The second advance of $15.0 million (“Tranche 2”) was drawn by the Company on March 29, 2021. The third advance of $15.0 million (“Tranche 3”) expired on December 31, 2021. The borrowings under the Prior Term Loan bear interest at the sum of a fixed percentage spread and the greater of (i) 1.80% or (ii) one month SOFR plus 0.1%.\n\nOn March 31, 2023, the Company entered into an Amended and Restated Credit, Security and Guaranty Agreement (Term Loan) (the “Term Loan Credit Agreement”) which amended and restated the Prior Term Loan Credit Agreement. The Term Loan Credit Agreement provides a secured term loan facility in an aggregate principal amount of up to $75.0 million. The Company borrowed the first advance of $40.0 million (“Tranche 1”) and the second advance of $15.0 million (“Tranche 2”) on the closing date to refinance the term loans under the Prior Term Loan Credit Agreement. Under the terms of the Term Loan Credit Agreement, (i) the third advance of $10.0 million (“Tranche 3”) was available to the Company through July 1, 2024, and (ii) the fourth advance of $10.0 million (“Tranche 4”), was available to the Company through July 1, 2025, subject to the Company’s satisfaction of certain other conditions described in the Term Loan Credit Agreement.\n\nTranche 1, Tranche 2, Tranche 3, and Tranche 4, each bear interest at a floating rate equal to the sum of the Term SOFR rate (subject to a floor of 1.00%) plus 6.50%. Interest on each term loan advance is due and payable monthly in arrears. Interest only payments are due for the first 36 months, and the remaining payments are due over the remaining 24 months. The interest only payment period can be extended for 12 months upon achievement of a specified trailing 12 month net revenue target. The interest rate at December 31, 2025 is approximately 10.7%.\n\n106\n\n \n\nOn September 1, 2023, the Company entered into Amendment 1 of the Term Loan Credit Agreement. At the close of this amendment, the Company borrowed $5.0 million available under Tranche 3. On January 5, 2024 the Company entered into Amendment 2 of the Term Loan Credit Agreement which was effective December 31, 2023, which removed the minimum revenue condition applicable to the remaining $5.0 million available in Tranche 3, which became eligible to be drawn at any time prior to July 1, 2024. The Company borrowed the remaining $5.0 million available in Tranche 3 on March 27, 2024.\n\nPrepayments of the term loans under the Term Loan Credit Agreement, in whole or in part, will be subject to early termination fees which decline each year through the term of the Term Loan Credit Agreement. The Company also must pay an annual administrative fee equal to a fractional percentage of the amount outstanding pursuant to the Term Loan Credit Agreement, and upon the final payment must also pay an exit fee of a percentage of the amount borrowed pursuant to the Term Loan Credit Agreement (the “Exit Fee”). The Company is required to pay a pro rata portion of the Exit Fee in connection with any prepayment. The Company uses the effective interest method to recognize the Exit Fee over the term of the debt.\n\nThe Company also maintained a Credit, Security and Guaranty Agreement (Revolving Loan) (the “Prior Revolving Loan Credit Agreement”) with MidCap. The borrowing limit under the Prior Revolving Loan Credit Agreement was $15.0 million which had a maturity date of March 1, 2024. The amount borrowed under the Prior Revolving Loan Credit Agreement could be increased, upon request by the Company, by up to an additional $5.0 million, subject to agent and lender approval and the satisfaction of certain conditions.\n\nOn March 31, 2023, the Company entered into Amended and Restated Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Loan Credit Agreement”) which amended and restated the Prior Revolving Loan Credit Agreement and has a maturity date of March 1, 2028. The Revolving Loan Credit Agreement provides a secured revolving credit facility in an initial aggregate principal amount of up to $20.0 million. The Company may request an increase in the total commitments under the Revolving Loan Credit Agreement by up to an additional $15.0 million, subject to agent and lender approval and the satisfaction of certain conditions.\n\nLoans under the Revolving Loan Credit Agreement accrue interest at a floating rate equal to the Term SOFR rate (subject to a floor of 1.00%) plus 3.75%. Accrued interest on the revolving loans will be paid monthly and revolving loans may be borrowed, repaid and re-borrowed until March 1, 2028, when all outstanding amounts must be repaid. Termination or permanent reductions of the revolving loan commitment under the Revolving Loan Credit Agreement will be subject to termination fees which decline each year until the fourth anniversary of the Revolving Loan Credit Agreement, at which time there is no early termination fee.\n\nIn connection with the Revolving Loan Credit Agreement, the Company is required to pay customary fees, including an origination fee equal to a fractional percentage of the original commitment amount at closing (and an equivalent origination fee with respect to any increased commitments at the time of the applicable increase), a monthly unused line fee based upon the average daily unused allowable borrowing base of the revolving credit facility and a monthly collateral management fee based upon the average daily used portion of the revolving credit facility. The Company is also required to maintain a minimum drawn balance under the revolving line or pay interest on the minimum drawn balance.\n\n \n\nAs of December 31, 2025 and December 31, 2024, the Company had borrowed $19.0 million and $19.3 million, respectively, under the Revolving Loan Credit Agreement, which is included in “Debt – current” in the Company’s consolidated balance sheets.\n\nThe Term Loan Credit Agreement and Revolving Loan Credit Agreement contain certain financial and non-financial covenants, with which the Company was in compliance at December 31, 2025. Additionally, the Company’s obligations under both agreements are secured by a security interest in substantially all of the Company’s assets, with some exclusions.\n\n \n\nNote 9. Leases\n\nOperating Leases\n\nThe Company leases its office facilities, located in Concord, California and Amersfoort, the Netherlands, and certain equipment and automobiles under non-cancelable operating leases with initial terms in excess of one year that require the Company to pay operating costs, property taxes, insurance and maintenance. The operating leases expire at various dates through 2031, with certain of the leases providing for renewal options, provisions for adjusting future lease payments based on the consumer price index, and the right to terminate the lease early. The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement. The Company recorded the lease right-of-use asset and obligation at the present value of lease payments over the lease term. The rates implicit in the Company’s leases are generally not readily determinable. The Company must estimate its incremental borrowing rate to discount the lease payments to present value. Operating lease assets also include lease incentives.\n\nThe Company reduced its office space and ceased using approximately 15,000 square feet of rentable area of corporate office building during the third quarter of 2023. The Company recognized a loss of $1.7 million related to this facilities consolidation in the year ended December 31, 2023 included in “Restructuring” on the Company’s consolidated statement of operations.\n\nSupplemental cash flow information related to operating leases is as follows (dollars in thousands):\n\n107\n\n \n\n \n\n \n\nYear Ended\n\n \n\n \n\n \n\nDecember 31,\n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nCash payments for operating leases\n\n \n\n$\n\n3,726\n\n \n\n \n\n$\n\n3,684\n\n \n\n \n\n$\n\n4,188\n\n \n\nRight-of-use assets obtained in exchange for operating lease obligations\n\n \n\n \n\n4,125\n\n \n\n \n\n \n\n231\n\n \n\n \n\n \n\n1,476\n\n \n\n \n\n \n\n \n\n \n\n \n\nDecember 31, 2025\n\n \n\n \n\nDecember 31, 2024\n\n \n\nWeighted-average remaining lease term\n\n \n\n4.1 years\n\n \n\n \n\n4.8 years\n\n \n\nWeighted-average discount rate\n\n \n\n \n\n9.0\n\n%\n\n \n\n \n\n8.6\n\n%\n\n \n\nFuture minimum non-cancelable payments under operating leases as of December 31, 2025, were as follows (in thousands):\n\n \n\n \n\nOperating Leases\n\n \n\n2026\n\n \n\n \n\n$\n\n3,749\n\n \n\n2027\n\n \n\n \n\n \n\n4,020\n\n \n\n2028\n\n \n\n \n\n \n\n3,351\n\n \n\n2029\n\n \n\n \n\n \n\n3,392\n\n \n\n2030\n\n \n\n \n\n \n\n859\n\n \n\nThereafter\n\n \n\n \n\n \n\n—\n\n \n\nTotal future lease payments\n\n \n\n \n\n$\n\n15,371\n\n \n\nLess imputed interest\n\n \n\n \n\n \n\n2,313\n\n \n\nPresent value of lease liabilities (1)\n\n \n\n \n\n$\n\n13,058\n\n \n\n \n\n(1) Lease liabilities include those operating leases that we plan to sublease as a part of our facilities consolidation restructuring efforts. See Note 7 for additional information.\n\nDuring the years ended December 31, 2025, 2024 and 2023, the Company recorded operating lease expenses of $4.0 million, $3.9 million and $3.5 million, respectively. As of December 31, 2025, the Company had no leases that have not yet commenced.\n\n108\n\n \n\nNote 10. Commitments and Contingencies\n\nPurchase Commitments\n\nThe Company is party to agreements with certain providers for certain components of the INTERCEPT Blood System. Certain of these agreements require minimum purchase commitments from the Company. As of December 31, 2025, the Company had $40.3 million of short-term purchase commitments and $3.0 million of long-term purchase commitments, which are not recorded in the Company’s consolidated balance sheets.\n\n \n\nNote 11. Stockholders’ Equity\n\nSales Agreement\n\nOn December 11, 2020, the Company entered into the Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated (each a “Sales Agent” and collectively, the “Sales Agents”), under which the Company may issue and sell from time to time up to $100.0 million of the Company’s common stock through or to the Sales Agents, as sales agent or principal.\n\nOn March 1, 2023, the Company entered into Amendment No.1 to the Sales Agreement (the “Amended Sales Agreement”). Under the Amended Sales Agreement, the Company is able to issue and sell from time to time up to $96.8 million of the Company’s common stock through or to the Sales Agents, as sales agent or principal. Under the Amended Sales Agreement, each Sales Agent receives compensation based on an aggregate of 3% of the gross proceeds on the sale price per share of the Company’s common stock. The issuance and sale of these shares by the Company pursuant to the Amended Sales Agreement are deemed an “at-the-market” offering and are registered under the Securities Act of 1933, as amended.\n\nDuring the year ended December 31, 2025, no shares of the Company’s common stock were sold under the Amended Sales Agreement. At December 31, 2025, the Company had approximately $96.8 million of common stock available to be sold under the Amended Sales Agreement.\n\n \n\nNote 12. Stock-Based Compensation\n\nEmployee Stock Plans\n\nEmployee Stock Purchase Plan\n\nThe Company maintains an Employee Stock Purchase Plan (the “Purchase Plan”), which is intended to qualify as an employee stock purchase plan within the meaning of Section 423(b) of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”). Under the Purchase Plan, the Company’s Board of Directors may authorize participation by eligible employees, including officers, in periodic offerings. Under the Purchase Plan, eligible employee participants may purchase shares of common stock of the Company at a purchase price equal to 85% of the lower of the fair market value per share on the start date of the offering period or the fair market value per share on the purchase date. The Purchase Plan consists of a fixed offering period of 12 months with two purchase periods within each offering period. In June 2020, the Company’s stockholders approved an amendment and restatement of the Purchase Plan that increased the aggregate number of shares of common stock authorized for issuance under the Purchase Plan by 1.5 million shares. In June 2024, the Company’s stockholders approved an amendment and restatement of the Purchase Plan that increased the aggregate number of shares of common stock authorized for issuance under the Purchase Plan by 2.0 million shares. At December 31, 2025, the Company had 1.9 million shares available for future issuance.\n\nEquity Incentive Plans\n\nThe Company also maintains an equity compensation plan to provide long-term incentives for employees, contractors, and members of its Board of Directors.\n\n2008 Equity Incentive Plan\n\nPrior to the approval by the Company’s stockholders in June 2024 of the 2024 Equity Incentive Plan (the “2024 Plan”), the Company granted equity awards from the 2008 Equity Incentive Plan and its subsequent amendments (collectively, the “Amended 2008 Plan”). The Amended 2008 Plan allowed for the issuance of non-statutory and incentive stock options, restricted stock, restricted stock units (“RSUs”), stock appreciation rights, other stock-related awards, and performance awards which may be settled in cash, stock, or other property. In June 2019, the Company’s stockholders approved an amendment and restatement of the Amended 2008 Plan that increased the aggregate number of shares of common stock authorized for issuance by 11.8 million shares. In June 2020, the Company’s stockholders approved an amendment and restatement of the Amended 2008 Plan that increased the aggregate number of shares of common stock authorized for issuance by 5.0 million shares. In June 2021, the Company’s stockholders approved an amendment and restatement of the Amended 2008 Plan that increased the aggregate number of shares of common stock authorized for issuance by 7.6 million shares. In June 2022, the Company’s stockholders approved an amendment and restatement of the Amended 2008 Plan that increased the aggregate number of shares of common stock authorized for issuance by 12.0 million shares. In June 2023, the Company’s\n\n109\n\n \n\nstockholders approved an amendment and restatement of the Amended 2008 Plan that increased the aggregate number of shares of common stock authorized for issuance by 7.0 million shares. Following the approval by the Company’s stockholders in June 2024 of the 2024 Plan, no additional awards will be granted under the Amended 2008 plan. Option awards under the Amended 2008 Plan generally have a maximum term of ten years from the date of the award. The Amended 2008 Plan generally required options to be granted at 100% of the fair market value of the Company’s common stock subject to the option on the date of grant. Options granted by the Company to employees generally vest over four years. RSUs are measured based on the fair market value of the underlying stock on the date of grant. RSUs granted by the Company to employees generally vest over three to four years. Performance-based stock awards granted under the Amended 2008 Plan were limited to 500,000 shares of common stock per recipient per calendar year. Performance-based cash awards granted under the Amended 2008 Plan were limited to $1.0 million per recipient per calendar year. At December 31, 2025, 3.2 million shares of performance-based stock awards were outstanding.\n\n2024 Equity Incentive Plan\n\nIn June 2024, the Company’s stockholders approved the 2024 Plan. The 2024 Plan is intended as the successor to and continuation of the Amended 2008 Plan. No additional awards will be granted under the Amended 2008 Plan. The shares remaining available for grant under the Amended 2008 Plan as of the effective date of the 2024 Plan, plus an additional 5.0 million shares of common stock were initially available for grant and issuance under the 2024 Plan. In addition, the following shares of common stock subject to any outstanding award granted under either the Amended 2008 Plan or the Cerus Corporation Inducement Plan have or will become available for grant and issuance under the 2024 Plan: (i) any shares subject to such award that on or following the effective date of the 2024 Plan are not issued because such award expires or otherwise terminates without all of the shares covered by such award having been issued; (ii) any shares subject to such award that on or following the effective date of the 2024 Plan are not issued because such award is settled in cash; and (iii) any shares issued pursuant to such award that on or following the effective date of the 2024 Plan are forfeited back to or repurchased by us because of a failure to vest. In June 2025, the Company’s stockholders approved an amendment and restatement of the 2024 Plan that increased the aggregate number of shares of common stock authorized for issuance by 10.0 million shares. Option awards under the 2024 Plan generally have a maximum term of ten years from the date of the award. The 2024 Plan generally requires options to be granted at 100% of the fair market value of the Company’s common stock subject to the option on the date of grant. Options granted by the Company to employees generally vest over four years. RSUs are measured based on the fair market value of the underlying stock on the date of grant. RSUs granted by the Company to employees generally vest over two to four years.\n\nAt December 31, 2025, the Company had approximately 27.5 million shares of its common stock subject to a combination of outstanding options and unvested RSUs under the Amended 2008 Plan and the 2024 Plan, of which approximately 10.0 million shares and 17.5 million shares were subject to outstanding options and unvested RSUs, respectively. At December 31, 2025, approximately 15.1 million shares were available for future issuance under the 2024 Plan. The Company’s policy is to issue new shares of common stock upon the exercise of options or vesting of RSUs.\n\nActivity under the Company’s equity incentive plans related to stock options is set forth below (in thousands except per share amounts):\n\n \n\n \n\nNumber of\nOptions Outstanding\n\n \n\n \n\nWeighted Average\nExercise Price\nper Share\n\n \n\nBalance at December 31, 2024\n\n \n\n \n\n12,297\n\n \n\n \n\n$\n\n5.10\n\n \n\nGranted\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nExercised\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nForfeited/canceled\n\n \n\n \n\n(2,270\n\n)\n\n \n\n \n\n4.66\n\n \n\nBalance at December 31, 2025\n\n \n\n \n\n10,027\n\n \n\n \n\n \n\n5.20\n\n \n\n \n\nActivity under the Company’s equity incentive plans related to RSUs is set forth below (in thousands except per share amounts):\n\n \n\n \n\nNumber of\nRSUs Unvested\n\n \n\n \n\nWeighted Average\nGrant Date Fair Value\nper Share\n\n \n\nBalance at December 31, 2024\n\n \n\n \n\n13,661\n\n \n\n \n\n$\n\n2.73\n\n \n\nGranted (1)\n\n \n\n \n\n11,062\n\n \n\n \n\n \n\n1.52\n\n \n\nVested (1)\n\n \n\n \n\n(5,902\n\n)\n\n \n\n \n\n2.97\n\n \n\nForfeited (1)\n\n \n\n \n\n(1,317\n\n)\n\n \n\n \n\n2.41\n\n \n\nBalance at December 31, 2025\n\n \n\n \n\n17,504\n\n \n\n \n\n \n\n1.91\n\n \n\n(1) Includes shares issuable under performance-based restricted stock unit awards.\n\n110\n\n \n\n \n\nThe total fair value of RSUs as of their respective vesting dates, for the years ended December 31, 2025, 2024 and 2023, were $8.8 million, $8.4 million and $8.7 million, respectively.\n\nInformation regarding the Company’s stock options outstanding, stock options vested and expected to vest, and stock options exercisable at December 31, 2025, was as follows (in thousands except weighted average exercise price and remaining contractual term):\n\n \n\n \n\nNumber of Shares\n\n \n\n \n\nWeighted Average\nExercise Price\n\n \n\n \n\nWeighted Average\nRemaining\nContractual Term\n(Years)\n\n \n\nAggregate\nIntrinsic Value\n\n \n\nBalance at December 31, 2025\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nStock options outstanding\n\n \n\n \n\n10,027\n\n \n\n \n\n$\n\n5.20\n\n \n\n \n\n \n\n3.14\n\n \n\n \n\n—\n\n \n\nStock options vested and expected to vest\n\n \n\n \n\n10,027\n\n \n\n \n\n$\n\n5.20\n\n \n\n \n\n \n\n3.14\n\n \n\n \n\n—\n\n \n\nStock options exercisable\n\n \n\n \n\n9,946\n\n \n\n \n\n$\n\n5.19\n\n \n\n \n\n \n\n3.11\n\n \n\n \n\n—\n\n \n\nThe aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the stock option and the Company’s closing stock price on the last trading day of each respective fiscal period.\n\nThere were no stock options exercised during the years ended December 31, 2025, 2024 and 2023. The total intrinsic value of exercised stock options is calculated based on the difference between the exercise price and the quoted market price of the Company’s common stock as of the close of the exercise date.\n\nStock-based Compensation Expense\n\nStock-based compensation expense recognized on the Company’s consolidated statements of operations for the years ended December 31, 2025, 2024 and 2023, was as follows (in thousands):\n\n \n\n \n\nYear Ended December 31,\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nResearch and development\n\n \n\n$\n\n5,554\n\n \n\n \n\n$\n\n5,897\n\n \n\n \n\n$\n\n5,823\n\n \n\nSelling, general and administrative\n\n \n\n \n\n17,313\n\n \n\n \n\n \n\n16,970\n\n \n\n \n\n \n\n14,448\n\n \n\nTotal stock-based compensation expense\n\n \n\n$\n\n22,867\n\n \n\n \n\n$\n\n22,867\n\n \n\n \n\n$\n\n20,271\n\n \n\nStock-based compensation expense in the above table does not reflect any income taxes as the Company has experienced a history of net losses since its inception and has a nearly full valuation allowance on its deferred tax assets. In addition, there was neither income tax benefits realized related to stock-based compensation expense nor any stock-based compensation costs capitalized as part of an asset during the years ended December 31, 2025, 2024 and 2023.\n\nAs of December 31, 2025, the Company expects to recognize the remaining unamortized stock-based compensation expense of $0.2 million related to non-vested stock options and $14.2 million related to RSUs, net of estimated forfeitures, over an estimated remaining weighted average period of 0.2 years and 1.0 years, respectively.\n\nValuation Assumptions for Stock-based Compensation\n\nThe Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options and employee stock purchase plan rights. The Black-Scholes option-pricing model is affected by the Company’s stock price, as well as assumptions regarding a number of subjective variables, which include the expected term of the grants, actual and projected employee stock option exercise behaviors, including forfeitures, the Company’s expected stock price volatility, the risk-free interest rate and expected dividends. The fair value of RSUs is measured on the grant date based on the closing fair market value of the Company’s common stock. The Company recognizes the grant-date fair value of the stock award as stock-based compensation expense generally on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures.\n\nThe expected life of the stock options is based on observed historical exercise patterns. Groups of employees having similar historical exercise behavior are considered separately for valuation purposes. The Company estimates stock option forfeitures based on historical data for employee groups. The total number of stock options expected to vest is adjusted by actual and estimated forfeitures. For performance-based awards, stock-based compensation expense is recognized over the expected performance achievement period of individual performance milestones when the achievement of each individual performance milestone becomes probable.\n\nThe expected volatility is estimated by using historical volatility of the Company’s common stock. The risk-free interest rate is based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term commensurate with the expected term of the option. The Company does not anticipate paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero.\n\n111\n\n \n\nThe weighted average assumptions used to value the Company’s stock-based awards for the years ended December 31, 2025, 2024 and 2023, was as follows:\n\n \n\n \n\nYear Ended December 31,\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nEmployee Stock Purchase Plan Rights:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nExpected term (in years)\n\n \n\n \n\n0.74\n\n \n\n \n\n \n\n0.75\n\n \n\n \n\n \n\n0.75\n\n \n\nEstimated volatility\n\n \n\n \n\n65\n\n%\n\n \n\n \n\n79\n\n%\n\n \n\n \n\n70\n\n%\n\nRisk-free interest rate\n\n \n\n \n\n4.04\n\n%\n\n \n\n \n\n4.66\n\n%\n\n \n\n \n\n5.29\n\n%\n\nExpected dividend yield\n\n \n\n \n\n0\n\n%\n\n \n\n \n\n0\n\n%\n\n \n\n \n\n0\n\n%\n\n \n\nThere were no stock options granted during the years ended December 31, 2025, 2024, and 2023. The weighted average grant-date fair value of employee stock purchase rights during the years ended December 31, 2025, 2024 and 2023, was $0.53 per share, $0.92 per share and $0.88 per share, respectively.\n\n \n\nNote 13. Retirement Plan\n\nThe Company maintains a defined contribution savings plan (the “401(k) Plan”) that qualifies under the provisions of Section 401(k) of the Internal Revenue Code and covers eligible U.S. employees of the Company. Under the terms of the 401(k) Plan, eligible U.S. employees may make pre-tax dollar or post-tax (Roth) contributions of up to 60% of their eligible pay up to a maximum cap established by the IRS. The Company may contribute a discretionary percentage of qualified individual employee’s salaries, as defined, to the 401(k) Plan. In 2019, the Company began providing a 401(k) match, subject to certain limitations. Under the 401(k) match, the Company matches 50% of the first 6% of each employee’s 401(k) contribution, up to an annual maximum of $5,000. The employer match will vest immediately. In 2025, the Company added an after-tax contribution election which is not eligible for the 401(k) match and is not counted towards the IRS maximum cap that is applicable to pre-tax and Roth contributions.\n\n \n\nNote 14. Development and License Agreements\n\nAgreements with Fresenius\n\nIn May 2022, the Company entered into the Second Amended and Restated Supply and Manufacturing Agreement (“2022 Agreement”) with Fresenius Kabi AG, Fenwal France SAS, and Fenwal International, Inc. (collectively, “Fresenius”) for the manufacture and production of disposable sets for the INTERCEPT Blood System until December 31, 2031. Under the terms of the 2022 Agreement, Fresenius is obligated to manufacture, and Company is obligated to purchase, finished disposable kits for the platelet and plasma systems. Fresenius sources most of the components used in the production of disposable kits, except for certain other components that the Company sources from other third-parties and provides to Fresenius for inclusion into the finished disposable kits. The 2022 Agreement permits the Company to purchase sets for the platelet and plasma systems from third-parties to the extent necessary to maintain supply qualifications with such third-parties or where local or regional manufacturing is needed to obtain product registrations or sales. Fresenius will expand manufacturing of the disposable sets to three production facilities, following qualification and licensure of such additional facilities. The term of the 2022 Agreement will automatically renew for successive two-year periods unless terminated by either party upon two years’ prior written notice, in the case of the initial term, or one year prior written notice, in the case of any successive renewal term. Each party has normal and customary termination rights, including termination for material breach. Pricing under the 2022 Agreement for the initial term is based on volume purchases by the Company and subject to an annual adjustment based on variation in a price index.\n\nGovernment contracts\n\nIn June 2016, the Company entered into an agreement with BARDA (“2016 BARDA Agreement”) to support the Company’s development and implementation of pathogen reduction technology for platelet, plasma, and red blood cells.\n\nThe 2016 BARDA agreement and its subsequent modifications include a base period (the “Base Period”) and option periods (each, an “Option Period”). The agreement includes committed funding for clinical development of the INTERCEPT Blood System for red blood cells (the “red blood cell system”). In September 2023, BARDA committed an additional $3.5 million raising the committed funding to up to $185.5 million as of December 31, 2024. However, the potential for the exercise by BARDA of subsequent Option Periods that, if exercised by BARDA and completed, was reduced by $8.8 million and would bring the total funding opportunity to $270.2 million through September 2026. If exercised by BARDA, subsequent Option Periods would fund activities related to broader implementation of the platelet and plasma system or the red blood cell system in areas of emerging pathogens, clinical and regulatory development programs in support of the potential licensure of the red blood cell system in the U.S., and development, manufacturing and scale-up activities for the red blood cell system. The Company could be responsible for up to $1.4 million of co-investment if certain Option Periods are exercised. BARDA will make periodic assessments of the Company’s progress and the continuation of the agreement is based on the Company’s success in completing the required tasks under the Base Period and each exercised Option Period. BARDA has\n\n112\n\n \n\nrights under certain contract clauses to terminate the agreement, including the ability to terminate the agreement for convenience at any time. As of December 31, 2025 and December 31, 2024, $2.5 million and $2.4 million, respectively, of billed and unbilled amounts were included in “Accounts receivable, net” on the Company’s consolidated balance sheets related to the 2016 BARDA agreement.\n\nIn September 2024, the Company entered into a new agreement with BARDA (“2024 BARDA Agreement”). The 2024 BARDA agreement builds on the 2016 BARDA agreement and aims to further advance the development of the red blood cell system. The 2024 BARDA agreement includes access to funding that is intended to support a planned FDA modular premarket approval application and potential post-approval studies, accelerate development of an improved version of the red blood cell system, and scale up chemistry, manufacturing, and controls activities to enable a broad product launch, if approved. The six-year agreement with BARDA includes a base period (the “2024 Base Period”) with committed funding of up to $32.1 million, and subsequent option periods (each, a “2024 Option Period”) that, if exercised by BARDA and completed, would bring the total funding opportunity to $188.4 million as of December 31, 2024. The Company could be responsible for cost sharing of up to $60.1 million. BARDA will make periodic assessments of the Company’s progress, and the continuation of the agreement is based on the Company’s success in completing the required tasks under the 2024 Base Period and each 2024 Option Period (if and to the extent any 2024 Option Periods are exercised by BARDA). BARDA has rights under certain contract clauses to terminate the 2024 BARDA agreement, including the ability to terminate for convenience at any time. Under the contract, the Company will be reimbursed and recognize revenue as qualified direct contract costs are incurred plus allowable indirect costs, based on approved provisional indirect billing rates, which permit recovery of fringe benefits, overhead and general and administrative expenses. As of December 31, 2025 and December 31, 2024, $0.6 million and $0.1 million, respectively, of billed amount was included in “Accounts receivable, net” on the Company’s consolidated balance sheets related to the 2024 BARDA agreement.\n\nIn September 2020, the Company entered into a five-year agreement with the FDA for the development of next-generation compounds to optimize pathogen reduction treatment of whole blood to reduce the risk of transfusion-transmitted infections. The agreement, which ended in September 2025, had a total contract value of $11.1 million. As of December 31, 2025 and December 31, 2024, zero and $0.5 million, respectively, of billed and unbilled amounts were included in “Accounts receivable, net” on the Company’s consolidated balance sheets related to FDA.\n\nIn September 2022, the Company entered into an agreement with the U.S. Department of Defense, or DoD, Industrial Base Analysis and Sustainment program for the development of pathogen reduced, lyophilized cryoprecipitate (“Lyo-Cryo”) to treat bleeding due to trauma. In May 2023, the Company and the DoD entered into an amendment to extend the agreement to February 2027 and increased the total contract value from $9.1 million to $17.8 million. In July 2025, the Company and the DoD entered into an additional amendment to extend the agreement to September 2028 to incorporate the Lyo-Cryo manufacturing advancement project phase III clinical study, which increased the total contract value by $7.2 million to $25.0 million. The revenue associated with the DoD contract is recognized on the application of the cost-to-cost input method, which measures the extent of progress towards completion of the single performance obligation based on the ratio of actual costs incurred to the total estimated costs over the performance period of the agreement. Revenue is recorded as a percentage of the transaction price based on the extent of progress towards completion. The estimate of the Company’s measure of progress, which can include additional services, if any, and the estimate of any additional consideration for those additional services, if any, are included in the transaction price which is updated at each reporting date, and revenue is recognized on a cumulative catch-up basis. As such, management applies a certain amount of judgment in estimating both the services and the corresponding timeline through to the completion of the performance obligation, which are key inputs when using the cost-to-cost input method. Given that the estimate of the Company’s measure of progress is updated at each reporting date, and revenue is recognized on a cumulative catch-up basis, a significant change in the remaining estimated costs to complete the services (including revisions to transaction price) could have a significant impact on revenues previously recognized under this arrangement (including reversal of previously recognized revenue) at each reporting date.\n\nAs of December 31, 2025 and December 31, 2024, $0.4 million and zero, respectively of unbilled amount was included in “Prepaid and other current assets” on the Company’s consolidated balance sheets related to DoD. As of December 31, 2025 and December 31, 2024, zero and $1.0 million, respectively, of billed amount was included in “Accounts receivable, net” on the Company’s consolidated balance sheets related to DoD. As of December 31, 2025 and December 31, 2024, zero and $0.5 million, respectively, were included in “Deferred revenue” as contract liabilities on the Company’s consolidated balance sheets related to the DoD contract.\n\n \n\nNote 15. Income Taxes\n\n \n\nU.S and foreign components of consolidated loss before income taxes for the years ended December 31, 2025, 2024 and 2023, was as follows (in thousands):\n\n \n\n113\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nLoss before income taxes:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDomestic\n\n \n\n$\n\n(17,709\n\n)\n\n \n\n$\n\n(21,318\n\n)\n\n \n\n$\n\n(38,281\n\n)\n\nInternational\n\n \n\n \n\n2,426\n\n \n\n \n\n \n\n562\n\n \n\n \n\n \n\n959\n\n \n\n Loss before income taxes\n\n \n\n$\n\n(15,283\n\n)\n\n \n\n$\n\n(20,756\n\n)\n\n \n\n$\n\n(37,322\n\n)\n\n \n\n \n\nThe provision for income taxes for the years ended December 31, 2025, 2024 and 2023, was as follows (in thousands):\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nProvision for income taxes:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCurrent:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nForeign\n\n \n\n$\n\n338\n\n \n\n \n\n$\n\n130\n\n \n\n \n\n$\n\n285\n\n \n\nFederal\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nState\n\n \n\n \n\n11\n\n \n\n \n\n \n\n70\n\n \n\n \n\n \n\n36\n\n \n\nTotal current\n\n \n\n \n\n349\n\n \n\n \n\n \n\n200\n\n \n\n \n\n \n\n321\n\n \n\nDeferred:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nForeign\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nFederal\n\n \n\n \n\n3\n\n \n\n \n\n \n\n3\n\n \n\n \n\n \n\n2\n\n \n\nState\n\n \n\n \n\n2\n\n \n\n \n\n \n\n2\n\n \n\n \n\n \n\n2\n\n \n\nTotal deferred\n\n \n\n \n\n5\n\n \n\n \n\n \n\n5\n\n \n\n \n\n \n\n4\n\n \n\nProvision for income taxes\n\n \n\n$\n\n354\n\n \n\n \n\n$\n\n205\n\n \n\n \n\n$\n\n325\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nA summary of cash paid for income taxes, net of refunds received, for the year ended December 31, 2025 was as follows (in thousands):\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n2025\n\n \n\nFederal\n\n \n\n$\n\n—\n\n \n\nState\n\n \n\n \n\n \n\nPennsylvania\n\n \n\n \n\n34\n\n \n\nOther states\n\n \n\n \n\n27\n\n \n\nForeign\n\n \n\n \n\n \n\nNetherlands\n\n \n\n \n\n198\n\n \n\nFrance\n\n \n\n \n\n42\n\n \n\nTotal cash paid for income taxes, net of refunds\n\n \n\n$\n\n301\n\n \n\n \n\nSignificant components of the Company’s deferred tax assets and liabilities consisted of the following (in thousands):\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\nDeferred tax assets\n\n \n\n \n\n \n\n \n\n \n\n \n\nNet operating loss carryforwards\n\n \n\n$\n\n132,585\n\n \n\n \n\n$\n\n127,184\n\n \n\nResearch and development credit carryforwards\n\n \n\n \n\n31,323\n\n \n\n \n\n \n\n29,739\n\n \n\nCapitalized research and development\n\n \n\n \n\n27,362\n\n \n\n \n\n \n\n35,861\n\n \n\nCompensation items\n\n \n\n \n\n10,425\n\n \n\n \n\n \n\n9,437\n\n \n\nOther\n\n \n\n \n\n14,637\n\n \n\n \n\n \n\n13,933\n\n \n\nTotal deferred tax assets\n\n \n\n \n\n216,332\n\n \n\n \n\n \n\n216,154\n\n \n\nLess valuation allowance\n\n \n\n \n\n(214,026\n\n)\n\n \n\n \n\n(214,321\n\n)\n\nNet deferred tax assets\n\n \n\n \n\n2,306\n\n \n\n \n\n \n\n1,833\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDeferred tax liabilities\n\n \n\n \n\n \n\n \n\n \n\n \n\nOther\n\n \n\n \n\n(236\n\n)\n\n \n\n \n\n(226\n\n)\n\nRight of use asset\n\n \n\n \n\n(2,149\n\n)\n\n \n\n \n\n(1,676\n\n)\n\nTotal deferred tax liabilities\n\n \n\n \n\n(2,385\n\n)\n\n \n\n \n\n(1,902\n\n)\n\nLess valuation allowance\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nNet deferred tax liabilities\n\n \n\n$\n\n(79\n\n)\n\n \n\n$\n\n(69\n\n)\n\n \n\n114\n\n \n\nA reconciliation of the U.S. Federal statutory tax rate to our 2025 annual tax rate is as follows (in thousands):\n\n \n\n \n\n \n\nAmount\n\n \n\n \n\nTax Rate\n\n \n\nU.S. federal statutory tax rate\n\n \n\n$\n\n(3,209\n\n)\n\n \n\n \n\n21\n\n%\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nState income tax, net of federal benefit (1)\n\n \n\n \n\n11\n\n \n\n \n\n \n\n—\n\n \n\nForeign tax effects\n\n \n\n \n\n \n\n \n\n \n\n \n\nNetherlands\n\n \n\n \n\n \n\n \n\n \n\n \n\nForeign currency related items\n\n \n\n \n\n(222\n\n)\n\n \n\n \n\n2\n\n \n\nOther\n\n \n\n \n\n51\n\n \n\n \n\n \n\n—\n\n \n\nOther foreign jurisdictions\n\n \n\n \n\n(1\n\n)\n\n \n\n \n\n—\n\n \n\nTax Credits\n\n \n\n \n\n \n\n \n\n \n\n \n\nFederal research credits(2)\n\n \n\n \n\n(605\n\n)\n\n \n\n \n\n4\n\n \n\nChange in valuation allowance\n\n \n\n \n\n(1,678\n\n)\n\n \n\n \n\n11\n\n \n\nNontaxable or nondeductible items\n\n \n\n \n\n \n\n \n\n \n\n \n\nStock compensation(3)\n\n \n\n \n\n3,501\n\n \n\n \n\n \n\n(23\n\n)\n\nOther\n\n \n\n \n\n(56\n\n)\n\n \n\n \n\n—\n\n \n\nChanges in unrecognized tax benefits\n\n \n\n \n\n(30\n\n)\n\n \n\n \n\n—\n\n \n\nOther adjustments\n\n \n\n \n\n \n\n \n\n \n\n \n\nExpired federal carryovers of losses, credits and deductions\n\n \n\n \n\n2,592\n\n \n\n \n\n \n\n(17\n\n)\n\nTotal income tax expense\n\n \n\n$\n\n354\n\n \n\n \n\n \n\n(2\n\n%)\n\n(1) State taxes in California, Florida, Massachusetts, and Pennsylvania make up the majority (greater than 50%) of the tax effect in this category.\n\n(2) Current year amount generated net of prior year adjustments and expirations.\n\n(3) Net effects of programs including shortfalls and executive items.\n\n \n\nA reconciliation of the U.S. Federal statutory tax rate to our 2024 and 2023 annual tax rate is as follows (in thousands):\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nFederal statutory tax\n\n \n\n$\n\n(4,359\n\n)\n\n \n\n$\n\n(7,838\n\n)\n\nFederal research credits\n\n \n\n \n\n(853\n\n)\n\n \n\n \n\n(1,065\n\n)\n\nState research credits\n\n \n\n \n\n(767\n\n)\n\n \n\n \n\n(642\n\n)\n\nExpiration of federal carryovers\n\n \n\n \n\n5,206\n\n \n\n \n\n \n\n7,284\n\n \n\nChange in valuation allowance\n\n \n\n \n\n(2,357\n\n)\n\n \n\n \n\n1,361\n\n \n\nCompensation related items\n\n \n\n \n\n4,015\n\n \n\n \n\n \n\n3,257\n\n \n\nState taxes\n\n \n\n \n\n(259\n\n)\n\n \n\n \n\n(1,710\n\n)\n\nRevision to prior year items\n\n \n\n \n\n(676\n\n)\n\n \n\n \n\n(664\n\n)\n\nOther\n\n \n\n \n\n255\n\n \n\n \n\n \n\n342\n\n \n\nProvision for income taxes\n\n \n\n$\n\n205\n\n \n\n \n\n$\n\n325\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nThe valuation allowance decreased by $0.3 million for the year ended December 31, 2025, compared to the decrease of $2.6 million and increase $1.0 million for the years ended December 31, 2024 and 2023, respectively. The Company believes that, based on a number of factors, the available objective evidence creates sufficient uncertainty regarding the realizability of the deferred tax assets such that a valuation allowance has been recorded. These factors include the Company’s history of net losses since its inception, the need for regulatory approval of the Company’s products prior to commercialization and expected near-term future losses. The Company expects to maintain a valuation allowance until circumstances change.\n\nFor the year ended December 31, 2025, the Company reported pretax net losses on its consolidated statement of operations and calculated taxable losses for federal purposes and varying taxable income and losses for state purposes based on individual jurisdictions. The differences between reported net loss and taxable income or loss are due to differences between book accounting and the respective tax laws. The most notable differences are the treatment of research and development expenses and compensation related items.\n\nThe Company’s tax losses and credits are subject to varying carryforward periods. The gross amounts and dates of expiration of the significant carryforwards are as follows:\n\n115\n\n \n\n \n\n \n\n \n\n \n\n \n\nExpires\n\n \n\n \n\nExpires\n\n \n\n \n\nExpires\n\n \n\n \n\nNo\n\n \n\n \n\n \n\nTotal\n\n \n\n \n\n2026-2028\n\n \n\n \n\n2029-2035\n\n \n\n \n\n2036-2045\n\n \n\n \n\nExpiration\n\n \n\nFederal losses carryovers\n\n \n\n$\n\n584,015\n\n \n\n \n\n$\n\n82,920\n\n \n\n \n\n$\n\n199,210\n\n \n\n \n\n$\n\n74,375\n\n \n\n \n\n$\n\n227,510\n\n \n\nCalifornia loss carryovers\n\n \n\n \n\n108,035\n\n \n\n \n\n \n\n19,243\n\n \n\n \n\n \n\n48,774\n\n \n\n \n\n \n\n40,018\n\n \n\n \n\n \n\n—\n\n \n\nOther state loss carryovers\n\n \n\n \n\n52,119\n\n \n\n \n\n \n\n16\n\n \n\n \n\n \n\n5,175\n\n \n\n \n\n \n\n33,217\n\n \n\n \n\n \n\n13,711\n\n \n\nFederal research credits\n\n \n\n \n\n17,852\n\n \n\n \n\n \n\n1,117\n\n \n\n \n\n \n\n2,533\n\n \n\n \n\n \n\n14,202\n\n \n\n \n\n \n\n—\n\n \n\nCalifornia research credits\n\n \n\n \n\n16,887\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n16,887\n\n \n\nFederal foreign tax credits\n\n \n\n \n\n610\n\n \n\n \n\n \n\n610\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\n \n\nThe Company’s ability to utilize net operating loss and research and development credit carryforwards is limited by (a) its ability to generate future taxable income, (b) varying apportionment and allocation rules, and (c) limitations pursuant to the ownership change rules in accordance with Sections 382 and 383 of the Internal Revenue Code, as well as similar state provisions.\n\nThe Company’s unrecognized tax benefits primarily relate to federal and California research tax credits. These tax credits have not been utilized on any tax return and currently have no impact on the Company’s tax expense due to the Company’s operating losses and the related valuation allowances. There are additional unrecognized tax benefits related to foreign activities.\n\nThe following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):\n\n \n\n \n\nDecember 31,\n\n \n\n \n\nDecember 31,\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\nUnrecognized tax benefits at beginning of period\n\n \n\n$\n\n7,837\n\n \n\n \n\n$\n\n7,924\n\n \n\nDecreases related to expired carryforwards\n\n \n\n \n\n(82\n\n)\n\n \n\n \n\n(344\n\n)\n\nDecreases related to administrative proceedings\n\n \n\n \n\n—\n\n \n\n \n\n \n\n(127\n\n)\n\nIncreases related to prior year tax positions\n\n \n\n \n\n52\n\n \n\n \n\n \n\n94\n\n \n\nIncreases related to current year tax positions\n\n \n\n \n\n298\n\n \n\n \n\n \n\n290\n\n \n\nUnrecognized tax benefits at end of period\n\n \n\n$\n\n8,105\n\n \n\n \n\n$\n\n7,837\n\n \n\nThe Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense.\n\n \n\nNote 16. Segment, Customer and Geographic Information\n\n \n\nThe Company manages its business activities on a consolidated basis and operates in one reportable segment. The Company’s Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using loss from operations.\n\nSignificant expenses within loss from operations include cost of product revenue, research and development, and selling, general and administrative expenses, which are each separately presented on the Company’s Consolidated Statements of Operations.\n\nThe Company’s operations outside of the U.S. include a wholly-owned subsidiary headquartered in Europe. The Company’s operations in the U.S. are responsible for the R&D and global and domestic commercialization of the INTERCEPT Blood System, while operations in Europe are responsible for the commercialization efforts of the platelet and plasma systems in Europe, the Commonwealth of Independent States and the Middle East. Product revenues are attributed to each region based on the location of the customer, and in the case of non-product revenues, on the location of the collaboration partner.\n\nThe Company had the following significant customers that accounted for more than 10% of the Company’s total product revenue, during the years ended December 31, 2025, 2024 and 2023 (in percentages):\n\n \n\n \n\n \n\nYear Ended December 31,\n\n \n\n \n\n2025\n\n \n\n2024\n\n \n\n2023\n\nAmerican Red Cross\n\n \n\n33%\n\n \n\n35%\n\n \n\n35%\n\nÉtablissement Français du Sang\n\n \n\n10%\n\n \n\n11%\n\n \n\n12%\n\n \n\n \n\n116\n\n \n\nRevenues by geographical location were based on the location of the customer during the years ended December 31, 2025, 2024 and 2023, and was as follows (in thousands):\n\n \n\n \n\nYear Ended December 31,\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\n \n\n2023\n\n \n\nProduct revenue:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nUnited States\n\n \n\n$\n\n124,723\n\n \n\n \n\n$\n\n109,256\n\n \n\n \n\n$\n\n93,232\n\n \n\nFrance\n\n \n\n \n\n21,198\n\n \n\n \n\n \n\n19,692\n\n \n\n \n\n \n\n18,490\n\n \n\nOther countries\n\n \n\n \n\n60,212\n\n \n\n \n\n \n\n51,322\n\n \n\n \n\n \n\n44,645\n\n \n\nTotal product revenue\n\n \n\n \n\n206,133\n\n \n\n \n\n \n\n180,270\n\n \n\n \n\n \n\n156,367\n\n \n\nGovernment contract revenue:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nUnited States\n\n \n\n \n\n27,665\n\n \n\n \n\n \n\n21,051\n\n \n\n \n\n \n\n30,430\n\n \n\nTotal government contract revenue\n\n \n\n \n\n27,665\n\n \n\n \n\n \n\n21,051\n\n \n\n \n\n \n\n30,430\n\n \n\nTotal revenue\n\n \n\n$\n\n233,798\n\n \n\n \n\n$\n\n201,321\n\n \n\n \n\n$\n\n186,797\n\n \n\n \n\nLong-lived assets by geographical location at December 31, 2025 and December 31, 2024, were as follows (in thousands):\n\n \n\n \n\n \n\nDecember 31,\n\n \n\n \n\n \n\n2025\n\n \n\n \n\n2024\n\n \n\nUnited States\n\n \n\n$\n\n5,470\n\n \n\n \n\n$\n\n6,807\n\n \n\nEurope & other\n\n \n\n \n\n3,734\n\n \n\n \n\n \n\n347\n\n \n\nTotal long-lived assets\n\n \n\n$\n\n9,204\n\n \n\n \n\n$\n\n7,154\n\n \n\n \n\n117\n\n \n\nSIGNATURES\n\nPursuant to the requirement of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 2nd day of March, 2026.\n\nCERUS CORPORATION\n\n \n\n \n\nBy:\n\n/s/ William M. Greenman\n\nWilliam M. Greenman\n\nPresident and Chief Executive Officer\n\nEach person whose signature appears below constitutes and appoints William M. Greenman and Kevin D. Green, his or her true and lawful attorney-in-fact and agent, each acting alone, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments to the Annual Report on Form 10-K and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.\n\nPursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.\n\nSignature\n\nTitle\n\nDate\n\n \n\n \n\n \n\n/s/ william m. greenman\n\nWilliam M. Greenman\n\nPresident, Chief Executive\n\nOfficer and Chair of the Board of Directors\n\n(Principal Executive Officer)\n\nMarch 2, 2026\n\n \n\n \n\n \n\n/s/ kevin d. green\n\nKevin D. Green\n\nVice President, Finance and\n\nChief Financial Officer\n\n(Principal Financial and Accounting Officer)\n\nMarch 2, 2026\n\n \n\n \n\n \n\n/s/ eric h. bjerkholt\n\nEric H. Bjerkholt\n\nDirector\n\n \n\nMarch 2, 2026\n\n \n\n \n\n \n\n \n\n/s/   dean a. gregory\n\nDean A. Gregory\n\nDirector\n\nMarch 2, 2026\n\n \n\n \n\n/s/ Ann Lucena\n\nAnn Lucena\n\nDirector\n\nMarch 2, 2026\n\n \n\n \n\n \n\n/s/ timothy l. moore\n\nTimothy L. Moore\n\nDirector\n\nMarch 2, 2026\n\n \n\n \n\n \n\n/s/ jami nachtsheim\n\nJami Nachtsheim\n\nDirector\n\nMarch 2, 2026\n\n \n\n \n\n \n\n/s/ hua shan, md, ph.d.\n\nDirector\n\nMarch 2, 2026\n\nHua Shan, MD, Ph.D.\n\n \n\n \n\n \n\n/s/ frank witney, ph.d.\n\nFrank Witney, Ph.D.\n\nDirector\n\nMarch 2, 2026\n\n \n\n118"}